

Article

Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72

Jonathan Pettinger, Michael Carter, Keith Jones, and Matthew D. Cheeseman

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.9b01709 • Publication Date (Web): 14 Nov 2019

Downloaded from pubs.acs.org on November 15, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72

*Jonathan Pettinger, Michael Carter, Keith Jones, and Matthew D. Cheeseman**

Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research,
London SW7 3RP, United Kingdom.

KEYWORDS kinetic, covalent, irreversible, lysine, HSP72.

Abstract

The covalent inhibition mechanism of action, which overcomes competition with high affinity, high abundance substrates of challenging protein targets, can deliver effective chemical probes and drugs. The success of this strategy has centered on exposed cysteine residues as nucleophiles but the low abundance of cysteine in the proteome has limited its application. We recently reported our discovery that lysine-56 in the difficult to drug target, HSP72, could form a covalent bond with a small molecule

inhibitor. We now disclose the optimization of these targeted covalent inhibitors using rational design. Essential to our optimization was the development of a new covalent fluorescence polarization assay, which allows for the direct measurement of the key kinetic parameter in covalent inhibitor design, k_{inact}/K_i , extrapolation of the underlying parameters, k_{inact} and K_i , and direct comparison to reversible analogues. Using our approach, we demonstrate a >100-fold enhancement in covalent efficiency and key learnings in lysine selective electrophile optimization.

Introduction

Despite many of our most important drugs utilizing irreversible covalent inhibition of an enzyme,¹ concerns relating to idiosyncratic toxicity led to the near exclusion of this mechanism of action (MOA) from drug discovery programmes.² The recent renaissance in covalent inhibitors is in large part due to their inherent advantage over reversible counterparts for antagonising proteins that have high-affinity, high-abundance natural substrates.³ Whilst the previous generation of irreversible inhibitor drugs were discovered by serendipity or were natural products, the rational design strategy for modern targeted covalent inhibitors (TCIs) focuses on exploiting high

1
2
3 resolution small-molecule/protein X-ray crystal structures of high affinity reversible
4
5
6
7 ligands to target active site, solvent-exposed cysteine residues with sparingly reactive
8
9
10 electrophiles.⁴ Unfortunately, the rarity of cysteine in the proteome has limited its
11
12
13 application,⁵ leading to an increased interest in targeting other potentially nucleophilic
14
15
16
17 residues.⁶⁻⁸
18
19
20
21

22 Depending on the length of exposure and the concentration, TCIs utilize both
23
24
25 reversible and irreversible occupancy of a protein (**Figure 1B**).⁹ Defining a TCI only via
26
27
28 an IC₅₀ value can be limiting for rational design, as the inhibitor (I) will inevitably appear
29
30
31 more potent with increasing pre-incubation time. TCIs typically react via a two-step
32
33
34
35 MOA (**Figure 1A**); initially binding to the protein (E) in a reversible manner to generate
36
37
38 a non-covalent complex (EI). The occupancy of the reversible complex is determined
39
40
41
42 by the free concentration of the TCI and the equilibrium constant K_i . The reversible
43
44
45 complex can then undergo covalent bond formation as determined by the first-order
46
47
48 rate constant k_{inact} to give the covalent complex (E-I). These fundamental parameters
49
50
51
52 describe the efficiency of the TCI but cannot be determined directly from assay data.
53
54
55
56
57
58
59
60




Figure 1. Simulated data describing the MOA and kinetic parameters used to quantify the activity of TCIs. (A) TCI two-step binding mechanism. (B) The two components of TCI MOA, both reversible and covalent occupancy contribute to total target occupancy at a given concentration and time. Left = covalent occupancy (%CO) and right total occupancy (%TO), both simulated using $K_I = 1 \mu\text{M}$ and $k_{inact} = 0.069 \text{ min}^{-1}$. FO = fraction reversible occupancy (see supporting information for derivation). (C) Determination of the essential second order rate constant k_{inact}/K_I from the concentration dependent k_{obs} pseudo-first-order rate constant. Left = example where $K_I < [I]$ so k_{inact} and K_I can be deconvoluted. Right = example where $K_I \gg [I]$ so the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

individual kinetic parameters cannot be distinguished. (D) Nucleoside-derived

reversible **1** and covalent inhibitor **2** of HSP72.

TCI activity is described by an equation analogous to the Michaelis-Menten equation. When normalized for protein concentration, the rate of covalent bond formation can be quantified by the pseudo first order rate constant, k_{obs} (Figure 1C). Because of the reversible binding event, k_{obs} is not a true constant, as its value is dependent on the concentration of the TCI. At TCI concentrations approaching binding site saturation, k_{obs} tends to the constant, k_{inact} , equivalent to the half-life of the reaction at a theoretical infinite concentration ($t_{1/2}^{inf}$).¹⁰ $[I]$ at $k_{inact}/2$ determines the pseudo-equilibrium constant K_i , equivalent to K_m when describing enzyme substrates. The true reversible equilibrium constant for the process, K_i , is often used interchangeably with K_i but this is only a fair assumption when $k_{inact} \ll k_{off}$ ¹¹ and this may not be true for tight-reversible binding TCIs. At concentrations much lower than K_i , the response of k_{obs} to changing TCI concentration becomes linear. The gradient of this relationship gives the second order rate constant k_{inact}/K_i , which is the key kinetic parameter that describes the efficiency of the reaction and its optimization is the primary goal of any TCI discovery effort towards a chemical probe (Figure 1C).

Analysis of the k_{inact}/K_i parameter clearly demonstrates that there are two strategies for TCI optimization: firstly, through the reduction of K_i by increasing the reversible

1
2
3 affinity of the ligand for the target protein, and secondly by increasing k_{inact} . The
4
5
6
7 optimization of k_{inact} differs from simply increasing the intrinsic reactivity of the
8
9
10 electrophile, as this would likely lead to greater off-target activity; instead, k_{inact}
11
12
13 optimization focuses on the particular environment within the protein binding site
14
15
16 compared to bulk aqueous solvent.¹² The effect of solvent dielectric constant, proximal
17
18
19 residues, perturbed pK_a and the tightly controlled bond angles and distances resulting
20
21
22 from the reversible binding of the ligand, can lead to a dramatically enhanced rate of
23
24
25 covalent bond formation and high selectivity. This effect of binding site rate
26
27
28 enhancement has led to effective, highly selective and successful TCI design of KRAS
29
30
31 G12C inhibitors, which display very weak reversible affinity but exploit extremely high
32
33
34
35
36
37
38 k_{inact} values with sparingly low intrinsic reactivity electrophiles, resulting in k_{inact}/K_I
39
40
41 values suitable for in vivo efficacy.^{13, 14}
42
43
44
45

46 Heat shock 70 kDa protein 1 (HSP72) is a member of the HSP70 family of molecular
47
48
49 chaperones. It is an ATPase that binds misfolded proteins, stabilizing the cellular
50
51
52 environment and allowing the cell to return to homeostasis.¹⁵ HSP72 is induced in an
53
54
55 HSF1 dependent manner when the cell is undergoing stress and is overexpressed in
56
57
58
59
60

several cancer cell types.¹⁶ This overexpression is correlated with metastasis, poor prognosis and resistance to chemotherapy in patients.¹⁷ Because of the clear role of HSP72 in cancer, it has become an important target in drug discovery but despite considerable research effort, there is currently no potent, selective, cellularly active chemical probe to study the function of HSP72 in cancer cells.

The nucleotide-binding domain (NBD) of HSP72 (HSP72-NBD) can be reversibly targeted with a series of *bis*-aryl nucleoside-derived inhibitors (**Figure 1D**), which display very high apparent affinity in biochemical assays but suffer a steep drop off in activity in cancer cells.¹⁸ We hypothesized that the poor cellular activity of this chemotype was due to competition with the high affinity (K_M for ATP = ~1 μ M) high abundance (~5 mM)¹⁹ substrate of HSP72, ATP. We recently reported the discovery that lysine-56 can be selectively targeted with an acrylate-derived TCI **2** (**Figure 1D**).²⁰ Targeting lysine residues with TCIs presents a number of unique challenges and is still in its infancy²¹ but the greater prevalence of lysine in the proteome²² could result in more wide ranging applications of the irreversible inhibitor paradigm than has so far been possible through the rational targeting of cysteine.

As part of our continuing effort to develop strategies and techniques to discover lysine-targeting covalent ligands, we now report the disclosure of a HSP72 TCI, where our approach led to a 108-fold improvement in k_{inact}/K_i . Critical to the optimization was the development of a covalent fluorescence polarization (covalent FP) assay that can distinguish between the reversible and covalent components of target occupancy, allowing for direct comparison between covalent and reversible analogues, which is essential for correct structure activity relationship (SAR) interpretation. The covalent FP-assay will be widely applicable to the optimization of TCIs of other non-enzymatic or poorly catalytic proteins.

Results and Discussion

Analysis of the first-generation lysine-56 TCI binding mode and optimization of K_i

Exploiting extensive mass spectrometry studies, single-point mutant proteins and through the design of several key control compounds, we had previously demonstrated that our first-generation acrylate TCI **2** (Figure 1D) was both highly selective for lysine-56 and that an initial reversible binding step was critical to its MOA. However, the rate of reaction of **2** was very slow, requiring >24 h exposure, even at

1
2
3
4 high concentrations, before the intact protein MS indicated complete formation of the
5
6
7 covalent complex.²⁰ Therefore, our aim was to develop a strategy to optimize lysine-
8
9
10 56 targeting TCIs of HSP72 towards a potentially cell active chemical probe.
11
12

13
14 To redesign the second-generation TCI with increased potency, we analyzed our
15
16
17 two previously reported co-crystal structures of HSP72-NBD with acrylate TCI 2
18
19
20 reversibly bound.²⁰ These structures revealed two distinct binding modes and protein-
21
22
23
24 residue conformations, which we hypothesized were both essential for the efficiency
25
26
27
28 of the covalent inhibition MOA (**Figure 2A/B**).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Analysis of Lys56-targeting TCI binding modes. The tertiary conformation of the protein is maintained in the previously described semi-open form in all structures and modeling. The polar interactions of the adenine-type base and ribose are maintained in each binding mode. All diagrams were adapted from analysis using MOE (2014.09) and PyMOL Molecular Graphics System, Version 2.0 Schrödinger,

1
2
3
4 LLC. 2.2.3 A: Tyr15 up-conformation. The acrylate electrophile of **2** forms a π -stack
5
6
7 interaction with Tyr15 and a hydrogen bond with Thr-37. In this reversible complex,
8
9
10 the electrophile is too far from Lys56 to form a covalent bond (PDB: 5MKR). B: Tyr15
11
12
13 down-conformation. Following rotation of Tyr15, rotation around the linker of **2** now
14
15
16 positions the acrylate electrophile in close proximity to Lys56, suitable for covalent
17
18
19 bond formation in this pre-covalent complex. The acrylate moiety was not observed in
20
21
22 the electron density due to flexibility so was modelled to estimate distances (PDB:
23
24
25 5MKS). C: Binding mode of the high affinity reversible HSP72 inhibitor **1** in the Tyr15
26
27
28 up-conformation (PDB: 4IO8). D: Model of a putative binding mode for a high affinity
29
30
31 Lys56-targeting TCI. With Tyr15 in a down-conformation, rotation of the benzylic ether
32
33
34 positions a potential *para*-electrophile at an appropriate distance from Lys56 in a pre-
35
36
37 covalent complex. E: Three-step MOA, TCI binds HSP72 to form the reversible
38
39
40 complex (EI) before transition to the pre-covalent complex (EI*) that can result in
41
42
43 formation of the covalent bond and the irreversible complex (E-I).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In the putative reversible complex of acrylate TCI **2** (**Figure 2A**, PDB: 5MKR),²⁰ Tyr15 was in an up-conformation, blocking any direct vector from the ligand to the nucleophilic Lys56. The electrophilic acrylate moiety formed an eclipsed conformation, resulting in a π -stack interaction with Tyr15 and a hydrogen bond to Thr37. In the putative pre-covalent complex (**Figure 2B**, PDB: 5MKS)²⁰ the electrophile was observed in an elongated conformation and with Tyr15 in a down-conformation.^{23, 24} The conformational flip of Tyr15 allowed the acrylate moiety to position proximally to the Lys56 nucleophile, which is essential for covalent bond formation. The hydrogen bonding array of the 8-aminoadenosine-motif and the position of the lipophilic *p*-chlorophenyl substituent were maintained in both binding modes. From this analysis, we proposed that the MOA of a HSP72 TCI proceeds via a three-step mechanism (**Figure 2E**). Firstly, the TCI binds HSP72 to give a reversible complex (EI) that would contribute to the reversible occupancy but could not lead directly to covalent occupancy. Transition of the reversible complex (EI) to the pre-covalent complex (EI*) would be essential for the formation of the covalent bond and the resulting irreversible complex (E-I). Optimization of the affinity for the reversible complex would still result in increased potency of the covalent bond formation, although K_i would now describe

a pseudo-equilibrium constant as a combination of the microscopic rate constants for the formation of the encounter complex and conformational switch, in a manner consistent with an induced fit binding MOA.²⁵ This would also assume that the conformational flexibility of Tyr15 is sufficient to allow transition to the pre-covalent complex and access the Lys56 nucleophile, so that covalent bond formation is rate determining in k_{inact} .

To optimize the reversible affinity of our TCI, we aimed to exploit the high affinity 5'-*O*-benzyl class of HSP72 inhibitors (**Figure 2C**). Analysis of the reversible complex (PDB: 4IO8)²⁶ of nitrile **1** (FP-Assay $pK_i > 6.70$, $K_i < 0.20$ μM , $N=3$)^{27, 28} revealed that this ligand forms similar polar and lipophilic interactions in the 8-aminoadenosine- and *p*-chlorophenyl-regions of HSP72-NBD as our acrylate TCI **2**. Importantly, the 5'-*O*-benzyl substituent occupies the same pocket as the acrylate moiety, so we hypothesized that a benzyl group with an appropriately positioned electrophile could exploit both the high affinity reversible complex and could transition to the pre-covalent complex (**Figure 2D**) in a similar putative three-step mechanism as our acrylate TCI **2**. To assess whether the proposed transition of the reversible to the pre-covalent complex was viable (**Figure 3B**), we carried out a rapid overlay of chemical structures

(ROCS)²⁹ ligand based analysis on the favorability of the linker torsional angles in this conformationally restricted structure, as this would be critical if we were to incorporate a 5'-benzylic substituent in our TCI design. Through alignment of the 5'-*O*-benzyl motif of **1** to the pre-covalent complex acrylate conformation of **2** and by comparison with known conformations of this chemotype in the Cambridge Structural Database (CSD)³⁰ (**Figure 3C**), it was demonstrated that a second generation inhibitor could adopt an acceptable benzylic torsional angle, resulting in a viable conformation for covalent bond formation. Finally, in this conformation the *para*-position gave the shortest distance to Lys56 (**Figure 3D**), so an electrophile at this position was incorporated to complete our rational design hypothesis for the second generation HSP72 TCI.





Figure 3. Conformation analysis of the proposed second generation HSP72 TCI. A: Overlay of the acrylate TCI 2 (green) and the high affinity reversible inhibitor 1 (cyan). B: Overlay of the acrylate TCI 2 (green) and the proposed conformation of the second-generation TCI (cyan) in the pre-covalent complex. The generic electrophile is represented as a purple sphere. C: Frequency distribution of torsional angles for 5'-*O*-adenosine derivatives observed in the CSD, the green line represents the desired torsional angle. D: At the desired torsional angle, the modelled distances to Lys56 from different ring positions.

Selection and synthesis of a lysine-targeting warhead and optimization of k_{inact} . Our first-generation TCI **2** utilized an acrylate warhead to form the covalent bond, which we hypothesized was sub-optimal for targeting lysine residues in proteins. Lysine is a hard nucleophile so should display an enhanced rate of reaction with hard electrophiles but few lysine-selective electrophiles have so far been described in the literature.³¹ A recent study by Campos et al. successfully exploited activated phenolic esters as hard electrophiles to target the catalytic lysine of PI3K δ .³² To incorporate this concept into the design of our second generation TCI, we developed a synthetic strategy that added an activated ester with a *p*-fluorophenol leaving group into the 5'-*para*-benzylic vector we had identified from our TCI MOA analysis.

The synthesis of the second-generation TCI began with benzylation of the 5'-hydroxyl of 2',3'-acetonide protected 6-chlororiboside **3** (Scheme 1). The order of addition is essential in this transformation to avoid oligomerization at the 6-chloro position; **3** was first treated with 4-(bromomethyl) benzonitrile, followed by exposure to NaH at 0 °C,¹⁸ which gave the 5'-ether **4** in 56% yield. S_NAr displacement with ammonia at the 6-position before selective oxidation with bromine at the 8-position, gave **5** in 59% yield over two steps as single regioisomer. A second S_NAr displacement

1
2
3
4 with 4-chlorobenzylamine gave the key covalent precursor **6** in 66% yield. To
5
6
7 synthesize the lysine-targeting warhead, the nitrile moiety of **6** was hydrolyzed under
8
9
10 basic conditions to give benzoic acid **7**, which then underwent coupling with 4-
11
12
13 fluorophenol using standard HATU conditions, and following acetonide deprotection,
14
15
16
17 gave the second-generation TCI **8** in 7 steps and 5% overall yield. Deprotection of the
18
19
20
21 intermediate **6** gave the reversible molecular matched pair (MMP) **9** in 47% yield.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60










Scheme 1. Synthesis of the second-generation lysine-56 targeting TCI.



Reagents and conditions: (i) 4-(bromomethyl) benzonitrile, NaH (60% in mineral oil), DMF, RT, 1h, 56%; (ii) 7M NH₃/MeOH, 110 °C, MW, 2 h, 82%; (iii) Br₂, K₂HPO₄·3H₂O, H₂O, 1,4-dioxane, RT, 1 h, 72%; (iv) 4-chlorobenzylamine, EtOH, 160 °C, MW, 1 h, 66%; (v) 2M NaOH, EtOH, 100 °C 3 h, 58%; (vi) 4-fluorophenol, HATU, DIPEA, DMF, RT, 18 h, 47%; (vii) TFA:H₂O (5:2), RT, 0.5 h, 85%; (viii) 5:2 TFA/H₂O, RT, 0.5 h, 47%.

Characterization of the second-generation TCI 8. To investigate the reversible affinity and the potential to form a covalent bond with Lys56 in HSP72-NBD with our second-generation TCI **8** (**Table 1**, Entry 3 and **Table 2**, Entry 2) we repeated our previously described analysis using the nucleotide-derived FP-assay, comparing the data to the first-generation TCI **2** (**Table 1**, Entry 1 and **Table 2**, Entry 1). Briefly, displacement of the nucleotide derived FP-probe by the ligand was used to determine an apparent (App.) K_i .²⁷ Because the bound fraction of the probe is dependent on the effective concentration of the protein, a time-dependent decrease following covalent bond formation should result in a shift in the binding curve for the TCI. The time-dependent FP-assay data revealed that the initial reversible binding affinity of activated ester **8** displayed a 7-fold improvement over our first-generation TCI **2** but was >13-fold weaker than the tight binding reversible nitrile MMP **9** (**Table 1**, Entry 2; $pK_i > 6.70$, $K_i < 0.20 \mu\text{M}$, $N=3$). Disappointingly, there was no clear time-dependence in the App. K_i and consistent with this result, analysis of the intact protein MS data for **8** also revealed no evidence of specific and selective covalent bond formation.
















Table 1. Kinetic and Affinity Analysis of Covalent and Non-Covalent Inhibitors of HSP72


| Entry | Cd |  | Time (h) | ^a App · <i>K_I</i> (μM) | ^b <i>K_{inact}</i> / <i>K_I</i> (M ⁻¹ s ⁻¹) | ^c <i>K_{inact}</i> (×10 ⁻⁴ s ⁻¹) | ^d <i>t</i> _{1/2} ^{inf} (min) | ^e Initial <i>K_I</i> (μM) | |
|-------|----|--|---|---|--|---|--|---|------|
| 1 | 2 |  |  | 0.08 3 19 46 | 17 7.2 3.7 | 0.86±0.2 2 | 0.16 | 720 | 18 |
| 2 | 9 | |  | NA | <0.2 0 | | | | |
| 3 | 8 | |  | 0.08 3 2.0 24 | 2.5 2.0 1.4 | | | | |
| 4 | 15 | |  | NA | 3.5 | | NA | | |
| 5 | 13 | |  | 0.08 3 1.0 2.0 | >200 >200 >200 | | | | |
| 6 | 14 | |  | 0.08 3 1.0 2.0 | 6.9 0.52 0.25 | 35±1.7 | 3.6 | 32 | 10 |
| 7 | 16 | | | ND | ND | 0.5±0.02 | ND | ND | >600 |
| 8 | 17 | | | ND | ND | | | | |
| | | | | 0.33 1.0 | 12 8.0 | 3.3±0.03 | 3.7 | 31 | 110 |
| 9 | 18 | | |  | 0.08 3 0.33 1.0 | 3.3 0.22 <0.2 0 | 93±2.9 | 4.4 | 26 |

All data was processed and analyzed using GraphPad Prism 7.04. All values are quoted to 2 significant figures. NA=Not Applicable, ND=Not Determined. ^aApp. *K_i*= Apparent *K_i*. Each concentration represent an n=3 statistical repeats, arithmetic mean±SEM. Each time course was generated from continuous measurements of each assay and assumes no significant TCI depletion. App. *K_i* values were calculated from

the fitted IC₅₀ curve using non-linear regression. (4 parameters) using the method in reference 27, see supporting information. ^bCalculated using the method described in **Figure 4**. Each value represents the arithmetic mean±SEM of n=3 biological repeats. ^cCalculated from the respective k_{inact}/K_i and initial K_i values using the method described in **Figure 4**. ^d $t_{1/2}^{inf} = \ln 2 / k_{inact}$. ^dCalculated from the IC₅₀ curves using non-linear regression (4 parameters) using the method described in **Figure 4**.

Table 2. HSP72 TCI Analysis

| Entry | Compound | ^a App. K_i | ^b Intact Protein MS | ^c k_{inact}/K_i |
|-------|----------|---|--|---|
| 1 | 2 |  |  |  |
| 2 | 8 |  |  | NA |
| 3 | 13 |  |  | NA |
| 4 | 14 |  |  |  |
| 5 | 16 |  | ND |  |
| 6 | 17 |  |  |  |



All data was processed and analyzed using GraphPad Prism 7.04. ^aApp. K_i = Apparent K_i . Each concentration represents n=3 statistical repeats, arithmetic mean \pm SEM. Each time course was generated from continuous measurements of each assay and assumes no significant TCI depletion. App. K_i values were calculated from the fitted IC_{50} curve using non-linear regression. (4 parameters) using the method in reference 27, see supporting information. ^bIntact protein mass spectrometry. Entry 1: HSP72-NBD [2.3 μ M] and TCI [200 μ M] incubated for the time indicated. Entries 2-4: HSP72-NBD [2.0 μ M] and TCI [20 μ M] incubated for the time indicated. The MS of the resulting protein/TCI adducts were analyzed using Agilent MassHunter Qualitative B.06. ^c k_{inact}/K_i values calculated from the covalent FP assay. The gradient of each slope was calculated from the linear regression, representative example of N=3 independent biological repeats, see supporting information for details.


From these data, we concluded that although our TCI design was successful in predicting that the binding site could accommodate the activated ester and maintain reversible affinity, we had failed to account for the stereoelectronic requirements of the electrophile. Efficient nucleophilic addition to the carbonyl must satisfy the correct Bürgi-Dunitz³³ and Flippin-Lodge angles³⁴ at appropriate reaction distances. This could not be achieved with *p*-fluorophenolate leaving group adopting the necessary vector-to-solvent in the conformationally restrictive TCI reversible binding mode, thus blocking covalent bond formation and the E-I complex.

Design and synthesis of the third generation HSP72 TCI. The aryl sulfonyl fluoride electrophile has recently become popular in both synthetic chemistry and chemical biology.^{35, 36} Sulfonyl fluorides are stable in water under physiologically relevant conditions and have previously been shown to react readily with lysine residues in proteins.^{35, 36} A recent study by Grimster et al. demonstrated that the electrophilicity of the moiety displays a strong dependence on the electronics of the attached aromatic ring and can be modulated to give an intrinsic reactivity against glutathione, comparable to chemical probe-relevant *N*-arylacrylamide electrophiles.³⁷ The solvation-dependent fluoride leaving group is less likely to form a steric clash and the

proposed S_N associative mechanism³⁸ should allow for a less restrictive stereoelectronic requirement for the reaction in the conformationally rigid protein binding site. We therefore hypothesized that incorporation of an aryl sulfonyl fluoride electrophile would be effective in our Lys56-targeting HSP72 third generation TCI. Unfortunately, our current methodology for the synthesis of 5'-benzylriboside ethers proved incompatible with the incorporation of the sulfonyl fluoride electrophile, so we adapted our TCI design to include an ester linker.

2',3'-acetonide protected adenosine **10** was selectively oxidized with bromine to give **11** in moderate yield. S_N Ar displacement with 4-chlorobenzylamine gave **12**, which then underwent selective esterification with 4-(fluorosulfonyl)benzoyl chloride to give **13** in 56% yield. The sulfonyl fluoride electrophile proved stable to the acetonide-deprotection conditions and gave the third generation TCI **14**, following treatment with TFA/H₂O, in 4 steps and 13% overall yield. To determine the effect of the 5'-ester linker on the reversible affinity, we synthesized the non-covalent ester MMP **15** of ether **9** in two steps from the primary alcohol intermediate **12** in 16% yield using 4-cyanobenzoyl chloride (**Scheme 2**).

Scheme 2. Synthesis of third generation aryl sulfonyl fluoride HSP72 TCIs



Reagents and conditions: (i) Br_2 , $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$, 1,4-dioxane, H_2O , RT, 0.5 h, 74%; (ii) 4-chlorobenzylamine, EtOH, 160 °C MW, 1h, 97%; (iii) 4-(fluorosulfonyl)benzoyl chloride, Et_3N , DMF, 0 °C, 4 h; 56% (iv) 5:2 TFA/ H_2O , RT, 0.5 h, 32%; (v) 4-cyanobenzoyl chloride, Et_3N , DMF, 0 °C, 3 h; (vi) 5:2 TFA/ H_2O , RT, 0.5 h, 16% over two steps; (vii) 4-(fluorosulfonyl)benzoic acid, HBTU, Et_3N , DMF, RT, 2 h; 66%; (viii) 5:2 TFA/ H_2O , RT, 0.5 h, 74%; (ix) 33% MeNH_2 in EtOH, 160 °C, MW, 1 h, 77%; (x) 4-(fluorosulfonyl)benzoic acid, HBTU, Et_3N , DMF, RT, 2 h; 35%; (xi) 5:2 TFA/ H_2O , RT, 0.5 h, 40%; (xii) quinoline-6-yl methanamine, EtOH, 160 °C, MW, 2 h, 8%; (xiii) 4-(fluorosulfonyl)benzoic acid, HBTU, Et_3N , DMF, RT, 2 h; 40%; (xiv) 5:2 TFA/ H_2O , RT, 0.5 h, 11%.

Characterization of the third generation TCI. The reversible 5'-ester analogue **15** displayed a binding affinity of $K_i=3.5\ \mu\text{M}$ ($pK_i=5.45\pm0.01$, $N=3$), >18-fold less potent than the tight-binding ether MMP **9** but sufficiently potent to investigate the role of the electrophile in HSP72 TCI design. Therefore, the third-generation ester sulfonyl fluoride TCI **14** was analyzed in the HSP72-NBD FP-assay. Pleasingly, **14** displayed a clear time-dependent shift in the probe displacement curve, consistent with covalent bond formation. The App. $K_i=17\ \mu\text{M}$ observed after 5 min exposure of TCI **14** was comparable to the reversible ester analogue **15**. The App. K_i appeared to increase in activity 24-fold over 2 h. The MMP irreversible control **13** showed no reversible binding affinity and no time-dependent displacement of the FP-probe. The analysis was repeated using the HSP72-NBD K56A mutant (see supporting information):²⁰ no time-dependent shift in the probe displacement curve was observed suggesting no significant formation of the covalent adduct with TCI **14** under the same conditions as the WT-HSP72-NBD, confirming the reaction specificity and requirement for an initial reversible binding event.

To confirm these results were due to covalent bond formation we then analyzed the reaction by intact-protein MS. A solution of HSP72-NBD and *p*-sulfonyl fluoride (SF)

TCI **14** (20 μ M **14** and 2.0 μ M HSP72-NBD) were incubated at 21 °C (room temperature) for 2 h. The experiment was repeated with irreversible control **13** under the same conditions. These data revealed that SF TCI **14** formed a covalent bond with HSP72-NBD, with the reaction going apparently to completion within three hours of exposure using this semi-quantitative assessment. The irreversible control MMP **13** gave no reaction under these conditions.

The covalent FP-assay. The timeframe of the App. K_i shift and intact protein MS with the third generation SF TCI **14** strongly indicated that it was far more efficient than the first-generation acrylate TCI **2** (Table 2, Entry 1 vs Table 2, Entry 4), as the formation of the covalent adduct was reduced from days to hours. However, using these data alone, it was not possible to quantify this optimization or to determine whether the increased activity was due to an increase in the reversible binding affinity K_i , an increase in efficiency of the covalent reaction k_{inact} or a mixture of the two, although analysis of the early time point App. K_i values did suggest the two analogues might possess comparable reversible affinity. To deconvolute the TCI optimization, it would be necessary to develop a new method to determine the kinetic parameters involved in the irreversible inhibition of HSP72-NBD.

Determining the kinetic parameters involved in covalent bond formation with proteins can be challenging.³⁹ Kinetic data often relies upon reaction rate changes evaluated from secondary readouts, such as substrate to product formation. Whilst this analysis can be accurate in determining the key second order rate constant for the process, k_{inact}/K_i , it can be difficult to accurately distinguish whether the retardation of the substrate to product reaction rate is due to reversible target occupancy or irreversible covalent bond formation. When attempting to determine k_{inact} , the reversible target occupancy is very high and approaching saturation, which significantly slows the substrate to product reaction separately from the covalent occupancy. Under these conditions, the time-dependent change in the rate of substrate to product reaction, necessary to determine k_{inact} is unavoidably very small and difficult to quantify accurately.⁹ This can lead to a significant underestimation of k_{inact} and a resulting overestimation of the binding affinity, K_i . Whilst a direct measurement of the rate of protein-TCI covalent adduct formation, the actual product of interest, using quantified mass spectrometry would circumvent many of these challenges, though determining kinetic parameters for tight-binding and high k_{inact} TCIs would still be difficult, this method is typically low throughput and cannot observe non-covalent adducts due to

the denaturing conditions of the assay. Therefore, TCI reversible affinities cannot be simply compared to their reversible non-covalent MMPs, a crucial requirement for efficient optimization.

Following analysis of the nucleotide-derived HSP72-NBD FP-assay, we hypothesized that it could be adapted to determine the kinetic parameters of covalent bond formation and would allow us to directly compare TCIs with reversible analogues.

The probe bound fraction (F_b), is determined by the affinity of the probe and the apparent concentration of the protein (see supporting information for details).²⁷

Changes in the bound fraction of the probe are observed through changes in the polarization of light emitted. Crucially, changes in the bound fraction are proportional to the effective concentration of protein. Displacement of the FP-probe by an inhibitor essentially decreases the effective concentration of protein, resulting in a decrease in the bound fraction. For a reversible inhibitor at equilibrium, the bound fraction remains constant at a given concentration. For an irreversible covalent inhibitor, the effective protein concentration decreases with time, which must result in a decrease in bound fraction. The time-dependent change in probe bound fraction could therefore be used

1
2
3 to quantify the covalent bound formation without secondary product formation or MS
4
5
6
7 analysis.
8
9

10 To quantify the covalent bond formation for our TCIs with HSP72-NBD, we would
11
12
13 need to interpret the time-dependent change in polarization of light from the probe.
14
15
16
17 The polarization must first be converted into the anisotropy, as the bound fraction of
18
19
20 the fluorescent probe is directly proportional to the anisotropy (A). However, F_b
21
22
23 displays a non-linear relationship with the effective protein concentration (E), such that
24
25
26
27 at high bound fractions ($F_b > 0.8$) small changes in anisotropy would equate to very
28
29
30 large changes in effective protein concentration, resulting in low accuracy. At low
31
32
33 bound fractions ($F_b < 0.4$) large changes in anisotropy would be needed to observe a
34
35
36 small change in effective protein concentration, which would result in low sensitivity
37
38
39 (see supporting information). Between these two extremes, the response of bound
40
41
42 fraction to changes in the effective protein concentration are linear to an acceptable
43
44
45 approximation.²⁷
46
47
48
49
50

51 To develop the HSP72 covalent FP assay we selected an initial protein
52
53
54 concentration that would lead to a high bound fraction ($F_b = 0.8$), as the reversible
55
56
57 occupancy of the protein would rapidly displace the probe and reduce F_b . If the initial
58
59
60

effective protein concentration was too low, this reversible displacement would move our analysis outside of the linear quantification window of the assay. As the concentration of the TCI is increased, the rate of change of F_b will increase. Following extrapolation of the linear regression to $t=0$, the initial F_b values are then plotted against the TCI concentration to generate a displacement curve and calculate the initial K_i . This quantifies the reversible affinity of the ligand, prior to the formation of the covalent bond and depletion of the effective protein concentration. The initial K_i value is then used to focus a second FP titration at TCI concentrations below initial K_i to estimate the crucial second order rate constant k_{inact}/K_i . Linear regression on the F_b versus time graph will give the rate of change of F_b , which is converted into the pseudo-first order rate constant k_{obs} , using the F_b values extrapolated from $t=0$. Finally, the plot of k_{obs} against the TCI concentration would give k_{inact}/K_i from the gradient of the linear region of the graph and by assuming $K_i=K_d$, we can estimate k_{inact} from this relationship and the initial K_i (Figure 4).




Figure 4. The covalent FP-assay to determine the efficiency of covalent bond formation. 1) Initial titration across a wide range of TCI concentrations and time-points. 2) Extrapolation of the time-dependent change in F_b to $t=0$. 3) Estimation of initial K_i from extrapolated $t=0$ F_b values, for an example of how to determine the K_i from an IC_{50} in the FP-assay see supporting information.²⁷ 4) A second focused titration on concentrations of $TCI < K_i$. 5) Gradient of time-dependent change in F_b used to calculate k_{obs} at a given concentration of TCI. 6) The gradient of the rate of change of k_{obs} with $[TCI]$ determines the second order rate constant k_{inact}/K_i . 7) By assuming

$K_i = K_d$, k_{inact} can be calculated from k_{inact}/K_i and converted to $t_{1/2}^{inf}$. See supporting information for details.

Kinetic characterization of the lysine-targeting TCIs. Using our analysis from the covalent FP-assay, third generation aryl SF TCI **14** displayed a second-order rate constant for the efficiency of the covalent bond formation with HSP72-NBD⁴⁰ of $k_{inact}/K_i = 35 \pm 1.7 \text{ M}^{-1}\text{s}^{-1}$ and k_{inact} calculated as $3.6 \times 10^{-4} \text{ s}^{-1}$, equivalent to $t_{1/2}^{inf} = 32 \text{ min}$ (**Table 1**, Entry 6). The half-life from the covalent FP-assay was consistent with the data from our intact-protein MS assay (**Table 2**, Entry 4) that showed complete modification of HSP72-NBD by SF TCI **14** (20 μM , 2 x initial K_i) within 3 hours (5.6 half-lives).

Comparing to the first-generation acrylate TCI **2** (**Table 1**, Entry 1 and **Table 2**, Entry 1): the aryl SF-TCI **14** displayed a 41-fold increase in k_{inact}/K_i , consistent with the time-dependent shift observed in the FP-assay. However, this improvement in covalent efficiency was not due to an increase in reversible affinity, as initial K_i only increased by 1.8-fold. The optimization of k_{inact}/K_i was derived largely by an improved k_{inact} (23-fold increase). The negative control MMP of aryl-SF **14**, acetone **13**, displayed no reactivity with accessible nucleophilic residues on HSP72-NBD to form a covalent adduct when assessed by intact protein MS, which suggested that the compatibility of the harder lysine electrophile was the driver of k_{inact} rather than intrinsic reactivity.

K_i optimization of the third-generation aryl SF TCI. Exploiting the versatility of the covalent FP-assay to directly compare covalent and non-covalent ligands, we designed a series of 5'-aryl-SF TCI analogues based on the known affinities of their reversible MMPs. Substitution at the 8-position of the adenine ring is essential for the affinity of this class of inhibitors and these diverse structures are synthetically tractable (**Scheme 2**).^{18, 23, 41, 42}

Analysis of the kinetics of the Lys56-targeting HSP72-NBD TCI series revealed that k_{inact} was comparable across the three aryl-SF analogues where a value could be determined (**Table 1**, Entries 6 and 8-9). The 8-nonsubstituted analogue **16** displayed an activity 70-fold weaker than the *N*-4-chlorobenzyl TCI **14**, demonstrating the importance of reversible affinity for TCI efficiency against this target. The 8-*N*-methyl substituted analogue **17**, decreased the covalent efficiency of the TCI 11-fold, which was predominately due to a drop in initial K_i consistent with the reported activity of its reversible MMP.²³ Finally, substitution with the 8-*N*-quinoline moiety, an analogue previously demonstrated to display the highest affinity as a reversible MMP,⁴¹ to give **18**, enhanced k_{inact}/K_i 2.7-fold compared to the *p*-chloro aryl-SF TCI **14**, consistent with

the 2.1-fold improvement in reversible affinity, and representing a 108-fold enhancement in covalent efficiency over our first generation acrylate TCI **2**.

Conclusion

The design, application and analysis of TCIs in a rational and quantitative manner, remains a critical challenge in covalent inhibitor drug discovery. The covalent FP-assay we developed utilized the time-dependent change in FP-probe bound-fraction to determine the fundamental parameters of covalent bond formation. For proteins like HSP72 with poor catalytic turnover in biochemical assays or non-enzymatic receptors and scaffolding proteins, the covalent FP-assay will be an important addition to the available methods to quantify and deconvolute the activity of TCIs, particularly as non-covalent reversible MMPs can be directly compared without the need to change assay formats.

We exploited our novel covalent FP-assay to continue our development of methods and strategies to discover lysine-targeting covalent inhibitors. Through our exhaustive understanding of the SAR and binding mode of nucleoside-derived reversible ligands of HSP72, we designed a next generation sulfonyl fluoride TCI **18**, which displayed a

108-fold enhancement in the critical second order rate constant, k_{inact}/K_i . Further analysis revealed that the rate enhancement was due to both optimization of K_i in a manner consistent with their MMP reversible analogues, and through a significant increase in k_{inact} . The failure of our activated ester second generation TCI **8** demonstrates the importance of electrophile design when targeting the harder nucleophile in lysine residues. The angles of attack in a conformationally restrictive environment, whilst maintaining the vectors and steric requirements to accommodate a leaving group, makes the design of lysine-selective electrophiles challenging. The sulfonyl fluoride electrophile was able to circumvent many of these difficulties, with its small fluoride leaving group and accommodating sulfur electrophilic center, and this represents a key learning in lysine-electrophile design. As we continue to progress towards a cell active chemical probe for HSP72 and as we improve our understanding and design strategy towards lysine-targeting covalent inhibitors of other challenging targets, the nature of the electrophile will prove crucial if we are to be successful.

EXPERIMENTAL SECTION

General Experimental. Unless otherwise stated, reactions were conducted in oven-dried glassware under an atmosphere of nitrogen or argon using anhydrous solvents. All commercially obtained reagents and solvents were used as received. Thin layer chromatography (TLC) was performed on pre-coated aluminum sheets of silica (60 F254 nm, Merck) and visualized using short-wave UV light. Flash column chromatography was carried out on Merck silica gel 60 (particle size 40–65 μm). Column chromatography was also performed on a Biotage SP1 or Biotage Isolera Four purification system using Biotage Flash silica cartridges (SNAP KP-Sil) or for reverse phase purifications SNAP Ultra C18 cartridges. Ion exchange chromatography was performed using acidic Isolute Flash SCX-II columns. ^1H NMR spectra were recorded on Bruker AMX500 (500 MHz) spectrometers using an internal deuterium lock. Chemical shifts are quoted in parts per million (ppm) using the following internal references: CDCl_3 (δH 7.26), MeOD (δH 3.31), and DMSO-d_6 (δH 2.50). Signal multiplicities are recorded as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets (dd), doublet of doublet of doublets (ddd), broad (br), apparent (app) or obscured (obs). Coupling constants, J , are measured to the nearest 0.1 Hz. ^{13}C NMR spectra were recorded on Bruker AMX500 spectrometers at 126 MHz using

an internal deuterium lock. Chemical shifts are quoted to 0.01 ppm, unless greater accuracy was required, using the following internal references: CDCl_3 (δC 77.0), MeOD (δC 49.0), and DMSO-d_6 (δC 39.5). High resolution mass spectra were recorded on an Agilent 1200 series HPLC and diode array detector coupled to a 6210 time-of-flight mass spectrometer with dual multimode APCI/ESI source or on a Waters Acquity UPLC and diode array detector coupled to a Waters G2 QToF mass spectrometer fitted with a multimode ESI/APCI source. For HRMS and LCMS extended mass (100 – 1000 AMU), analytical separation was carried out at 30 °C on a Merck Chromolith Flash column (RP-18e, 25 x 2 mm) using a flow rate of 0.75 mL/min in a 4-minute gradient elution with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A) and water (solvent B), both containing formic acid at 0.1%. Gradient elution was as follows: 5:95 (A/B) to 100:0 (A/B) over 2.5 min, 100:0 (A/B) for 1 min, and then reversion back to 5:95 (A/B) over 0.1 min, finally 5:95 (A/B) for 0.4 min. HRMS references: caffeine $[\text{M}+\text{H}]^+$ 195.087652; hexakis (2,2-difluoroethoxy)phosphazene $[\text{M}+\text{H}]^+$ 622.02896; and hexakis(1H,1H,3H-tetrafluoropentoxy)phosphazene $[\text{M}+\text{H}]^+$ 922.009798. For standard LCMS, analytical separation was carried out at 40 °C on a Merck Chromolith Flash column (RP-18e, 25

x 2 mm) using a flow rate of 1.5 mL/min in a 2-minute gradient elution with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A) and water (solvent B), both containing formic acid at 0.1%. Gradient elution was as follows: 5:95 (A/B) to 100:0 (A/B) over 1.25 min, 100:0 (A/B) for 0.5 min, and then reversion back to 5:95 (A/B) over 0.05 min, finally 5:95 (A/B) for 0.2 min. Infrared spectra were recorded on a Bruker Alpha-p FT-IR spectrometer. Absorption maxima (ν_{\max}) are quoted in wavenumbers (cm^{-1}). All compounds were >95% purity by HPLC analysis unless otherwise stated. The standard adenine and adenosine numbering has been used throughout. All compounds were >95% purity by LCMS analysis unless otherwise stated.

4-((((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((3,4-dichlorobenzyl)amino)-9*H*-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)benzonitrile 1. Synthesized via the method described by Williamson et al.¹⁸

3-(((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propyl acrylate 2. Synthesized via the method described by Pettinger et al.²⁰

4-((((3a*R*,4*R*,6*R*,6a*R*)-6-(6-chloro-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile **4**. 6-Chloro-9-[2,3-*O*-(1-methylethylidene)-*beta*-*D*-ribofuranosyl]-9*H*-Purine **3** (3.05 g, 9.34 mmol) and 4-(bromomethyl)benzonitrile (7.33 g, 37.4 mmol) were dissolved in DMF (80 mL) and stirred at room temperature for 5 minutes. Sodium hydride (60% in mineral oil, 0.41 g, 10.3 mmol) was then added and the reaction stirred at room temperature for a further 45 minutes. The reaction was quenched with 1% AcOH (20 mL), then taken up in EtOAc (60 mL) and water (60 mL). The organic extracts were washed with sat. NaCl (3 x 50 mL) and dried over MgSO₄. The solvent was then removed under reduced pressure to give the crude product, which was purified by silica gel chromatography with the Biotage SP1 purification system (Cyc/EtOAc 100:0 to 70:30) to give the title compound **4** as a colorless foam (2.3 g, 56%); ¹H NMR (600 MHz, CDCl₃) δH 8.73 (s, 1H), 8.30 (s, 1H), 7.55 (d, *J* = 8.3 Hz, 2H), 7.23 (d, *J* = 8.2 Hz, 2H), 6.23 (d, *J* = 2.3 Hz, 1H), 5.38 (dd, *J* = 6.1, 2.3 Hz, 1H), 5.00 (dd, *J* = 6.1, 2.5 Hz, 1H), 4.59 (app. dt, *J* = 4.1, 2.9 Hz, 1H), 4.50 (d, *J* = 12.7 Hz, 1H), 4.47 (d, *J* = 12.7 Hz, 1H), 3.75 (dd, *J* = 10.5, 3.1 Hz, 1H), 3.68 (dd, *J* = 10.6, 4.2 Hz, 1H), 1.64 (s, 3H), 1.42 (s, 3H); ¹³C NMR (151 MHz, CDCl₃) δC 152.21, 151.36, 151.05, 143.87, 142.34, 132.39, 127.82, 118.83, 118.61, 114.68, 112.02, 92.38, 86.40, 84.92, 81.79, 72.78, 71.01, 27.29, 25.50; HRMS (ESI) C₂₁H₂₁N₅O₄³⁵Cl (M+H⁺) requires 442.1277, found 442.1254; tR (LCMS) = 1.39 min.

4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-bromo-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile **5**. 4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-chloro-9*H*-purin-
9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile **4** (2.3 g,
5.21 mmol) was dissolved in ammonia (7N in MeOH, 20 mL, 140 mmol) and heated by
microwave at 110 °C for 2 hours. The solvent was removed under reduced pressure and the
subsequent residue partitioned between EtOAc (50 mL) and water (50 mL). The combined
organic extracts were washed with sat. NaCl (3 x 30 mL) and dried over MgSO₄. The solvent
was then removed under reduced pressure to give the crude product, which was purified by
silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to
60:40) to give 4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-9*H*-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile as a white
amorphous solid (1.81 g, 82%); ¹H NMR (600 MHz, CDCl₃) δH 8.30 (s, 1H), 7.92 (s, 1H), 7.54
(d, *J* = 8.3 Hz, 2H), 7.26 (obs. d, *J* = 8.0 Hz, 2H), 6.13 (d, *J* = 2.1 Hz, 1H), 5.58 (br. s, 2H),
5.44 (dd, *J* = 6.2, 2.2 Hz, 1H), 5.04 (dd, *J* = 6.2, 3.0 Hz, 1H), 4.55 – 4.48 (m, 3H), 3.73 (dd, *J*
= 10.4, 3.8 Hz, 1H), 3.67 (dd, *J* = 10.4, 5.5 Hz, 1H), 1.63 (s, 3H), 1.41 (s, 3H); ¹³C NMR (151
MHz, CDCl₃) δC 155.45, 153.25, 149.46, 142.99, 139.74, 132.30, 127.74, 120.33, 118.85,
114.50, 111.69, 91.56, 86.36, 84.60, 81.91, 72.60, 70.96, 27.32, 25.56; HRMS (ESI)
C₂₁H₂₃N₆O₄ (M+H⁺) requires 423.1775, found 423.1745; tR (LCMS) = 1.24 min; IR (FTIR-

ATR)/cm⁻¹ = 3313, 3141, 2987, 2938, 2230, 1641, 1600, 1470, 1417, 1373. 4-

(((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-

d][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile (1.62 g, 3.84 mmol) was dissolved in

1,4-dioxane (35.0 mL). A solution of K₂HPO₄·3H₂O (2.63 g, 11.53 mmol) and bromine

(1.54 g, 9.60 mmol) in water (35.0 mL) was then added dropwise to the stirred solution

of 100 at room temperature. After 1 hour, the reaction was quenched with sat. aq.

Na₂S₂O₃ solution (40 mL) and stirred for a further 2 minutes. The resulting mixture was

extracted with EtOAc (3 x 50 mL), then the combined organic layers were washed with

sat. NaCl (3 x 50 mL) and dried over MgSO₄. The solvent was then removed under

reduced pressure to give the crude product, which was purified by silica gel

chromatography with the Biotage SP1 purification system (Cyc/EtOAc 50:50 to 0:100)

to give the title compound **5** as a yellow oil (1.39 g, 72%); ¹H NMR (600 MHz, CDCl₃)

δH 8.16 (s, 1H), 7.54 (d, *J* = 8.3 Hz, 2H), 7.30 (d, *J* = 8.4 Hz, 2H), 6.21 (d, *J* = 1.7 Hz,

1H), 5.67 (dd, *J* = 6.4, 1.8 Hz, 1H), 5.61 (br. s, 2H), 5.16 (dd, *J* = 6.3, 3.8 Hz, 1H), 4.54

(d, *J* = 13.3 Hz, 1H), 4.48 (d, *J* = 13.3 Hz, 1H), 4.44 (app. dt, *J* = 7.5, 4.5 Hz, 1H), 3.67

(dd, *J* = 10.3, 4.8 Hz, 1H), 3.60 (dd, *J* = 10.3, 7.4 Hz, 1H), 1.63 (s, 3H), 1.40 (s, 3H);

¹³C NMR (151 MHz, CDCl₃) δC 154.24, 152.97, 150.51, 143.49, 132.22, 127.88,

127.73, 120.30, 118.96, 114.57, 111.47, 91.37, 86.98, 83.47, 82.21, 72.37, 70.64, 27.34, 25.60; HRMS (ESI) $C_{21}H_{22}N_6O_4^{79}Br$ ($M+H^+$) requires 501.0880, found 501.0871; tR (LCMS) = 1.46 min; IR (FTIR-ATR)/ cm^{-1} = 3322, 3172, 2987, 2228, 1639, 1597, 1577, 1454, 1373, 1290, 1205.

4-(((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-

dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile 6. 4-

(((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-bromo-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile **5** (0.98 g, 1.95 mmol) was dissolved in EtOH (16 mL) and added to 4-chlorobenzylamine (2.77 g, 19.5 mmol) and the reaction was heated in the microwave for 1 hour at 160 °C. The solvent was removed under reduced pressure and the resulting residue taken up in EtOAc (50 mL) and 1% aq. AcOH (50 mL). The product was extracted with EtOAc (3 x 40 mL), washed with 1% aq. AcOH (3 x 40 mL), sat. $NaHCO_3$ (3 x 40 mL) and sat. NaCl (40 mL) and dried over Na_2SO_4 . The solvent was removed under reduced pressure and the crude product was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 80:20) to give the title compound **6** as an orange foam (0.72 g, 66%); 1H NMR (600 MHz, $CDCl_3$) δ 8.17 (s, 1H), 7.55 (d, J = 8.3 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.19 – 7.15 (m, 4H), 6.23 (d, J = 3.3 Hz, 1H), 5.90 (app. t, J = 5.9 Hz, 1H), 5.33 (dd, J = 6.7, 3.3 Hz, 1H), 5.15 (br. s, 2H), 4.97 (dd, J = 6.7, 3.9 Hz, 1H),

4.45 (dd, J = 15.6, 6.0 Hz, 1H), 4.42 (dd, J = 15.5, 5.6 Hz, 1H), 4.30 – 4.26 (m, 3H), 3.73 (dd, J = 10.5, 3.0 Hz, 1H), 3.57 (dd, J = 10.5, 2.9 Hz, 1H), 1.62 (s, 3H), 1.38 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ C 152.18, 151.61, 150.34, 150.28, 142.30, 137.35, 133.37, 132.52, 128.87, 128.69, 127.74, 118.60, 117.58, 115.34, 112.08, 88.63, 83.86, 82.82, 80.14, 72.60, 69.50, 46.06, 27.41, 25.58; HRMS (ESI) $\text{C}_{28}\text{H}_{29}\text{N}_7\text{O}_4^{35}\text{Cl}$ ($\text{M}+\text{H}^+$) requires 562.1964, found 562.1922; t_R (LCMS) = 1.48 min; IR (FTIR-ATR)/ cm^{-1} = 3325, 2934, 2229, 1633, 1606, 1571, 1491, 1469, 1434, 1361, 1333, 1285, 1210.

4-(((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-

dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzoic acid 7. 4-

(((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-

dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile 6 (91 mg, 0.16

mmol) was dissolved in aq. NaOH (2M, 0.8 mL, 1.62 mmol) and ethanol (0.9 mL) and heated

in a sealed microwave vial at 110 °C for 3 hours. The reaction was cooled to room temperature

and neutralized to pH 7 with 1M HCl. The mixture was extracted with EtOAc (3 x 20 mL) and

the combined organic extracts were washed with sat. aq. NaHCO_3 (3 x 20 mL), sat. NaCl (3 x

20 mL) and dried over MgSO_4 . The solvent was then removed under reduced pressure to give

the crude product, which was purified by reverse-phase C18 chromatography with the Biotage

SP1 purification system (water/MeCN 70:30 to 0:100) to give the title compound **7** as a white

amorphous solid (55 mg, 58%); ¹H NMR (600 MHz, CDCl₃) δH 8.03 (s, 1H), 7.94 (d, *J* = 8.2 Hz, 2H), 7.24 (d, *J* = 8.4 Hz, 2H), 7.13 (d, *J* = 8.2 Hz, 2H), 7.10 (d, *J* = 7.9 Hz, 2H), 6.49 (br. s, 2H), 6.16 (d, *J* = 2.8 Hz, 1H), 6.05 (app. t, *J* = 6.0 Hz, 1H), 5.59 (dd, *J* = 6.4, 2.9 Hz, 1H), 5.01 (dd, *J* = 6.5, 3.2 Hz, 1H), 4.42 – 4.24 (m, 5H), 3.73 (dd, *J* = 10.6, 2.8 Hz, 1H), 3.64 (dd, *J* = 10.5, 3.0 Hz, 1H), 1.62 (s, 3H), 1.40 (s, 3H); ¹³C NMR (151 MHz, CDCl₃) δC 170.16, 152.14, 151.89, 149.52, 148.83, 141.29, 137.12, 133.33, 131.51, 130.14, 128.83, 128.71, 127.41, 116.69, 114.82, 89.87, 84.99, 82.80, 80.67, 73.51, 69.79, 45.80, 27.33, 25.55; tR (LCMS) = 1.47 min.

4-fluorophenyl 4-((((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)benzoate **8**. 4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzoic acid **7** (20 mg, 34 μmol) was dissolved in DMF (0.4 mL). HATU (16 mg, 41 μmol), then DIPEA (9 mg, 69 μmol) were added and the reaction stirred at room temperature for 1 minute. 4-Fluorophenol (12 mg, 0.10 mmol) was added and the reaction stirred at room temperature for 18 hours. The solvent was then removed under reduced pressure to give the crude product, which was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 80:20) to give 4-fluorophenyl 4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-

dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzoate as a yellow oil (11 mg, 47%); ¹H NMR (600 MHz, DMSO-*d*₆) δH 8.03 (d, *J* = 8.3 Hz, 2H), 7.89 (s, 1H), 7.49 (app. t, *J* = 6.0 Hz, 1H), 7.41 (d, *J* = 8.1 Hz, 2H), 7.40 – 7.28 (m, 8H), 6.52 (br. s, 2H), 6.13 (d, *J* = 2.4 Hz, 1H), 5.70 (dd, *J* = 6.3, 2.4 Hz, 1H), 5.07 (dd, *J* = 6.3, 3.3 Hz, 1H), 4.58 – 4.47 (m, 4H), 4.29 (app. td, *J* = 5.5, 3.3 Hz, 1H), 3.65 (dd, *J* = 10.5, 5.1 Hz, 1H), 3.53 (dd, *J* = 10.5, 6.2 Hz, 1H), 1.54 (s, 3H), 1.34 (s, 3H); ¹³C NMR (151 MHz, DMSO-*d*₆) δC 164.41, 152.56, 151.11, 149.20, 148.92, 146.69, 144.46, 138.71, 131.28, 129.81, 129.10, 128.10, 127.77, 127.38, 123.77 (d, *J* = 8.8 Hz), 117.06, 116.23, 116.08, 113.25, 87.51, 84.55, 81.89, 81.42, 71.54, 69.94, 44.72, 27.06, 25.29; ¹⁹F NMR (471 MHz, DMSO-*d*₆) δF -117.07; HRMS (ESI) C₃₄H₃₃N₆O₆³⁵ClF (M+H⁺) requires 675.2129, found 675.2037; tR (LCMS_extended) = 3.23 min. 4-fluorophenyl 4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzoate (5 mg, 7 μmol) was dissolved in a 5:2 mixture of TFA/H₂O (0.7 mL) and stirred at room temperature for 30 minutes. The solvent was then removed under reduced pressure to give the crude product, which was purified by reverse-phase C18 chromatography with the Biotage SP1 purification system (water/MeCN 80:20 to 0:100) to give the title compound **8** as a white amorphous solid (4 mg, 85%); ¹H NMR (600 MHz, DMSO-*d*₆) δH 8.02 (d, *J* = 8.3 Hz, 2H), 7.90 (s, 1H), 7.43 (d, *J* = 8.1 Hz, 2H), 7.36 – 7.29 (m, 8H), 7.13 (app. t, *J* = 6.0 Hz, 1H), 6.46 (br. s, 2H), 5.88 (d, *J*

= 5.8 Hz, 1H), 5.47 (br. app. s, 1H), 5.29 (br. app. s, 1H), 4.94 – 4.88 (m, 1H), 4.59 – 4.53 (m, 2H), 4.52 – 4.44 (m, 2H), 4.33 – 4.28 (m, 1H), 4.07 – 4.02 (m, 1H), 3.78 (dd, J = 10.7, 3.1 Hz, 1H), 3.65 (dd, J = 10.8, 4.5 Hz, 1H); ^{13}C NMR (151 MHz, DMSO- d_6) δC 164.35, 152.47, 151.27, 149.92, 148.92, 146.67, 144.36, 138.79, 131.20, 129.82, 128.83, 128.07, 127.81, 127.41, 123.75 (d, J = 8.7 Hz), 116.91, 116.23, 116.07, 86.92, 82.86, 71.69, 70.49, 70.39, 44.61, 40.06; HRMS (ESI) $\text{C}_{31}\text{H}_{29}\text{N}_6\text{O}_6^{35}\text{ClF}$ ($\text{M}+\text{H}^+$) requires 635.1816, found 635.1823; $t\text{R}$ (LCMS) = 1.64 min.

4-((((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methoxy)methyl)benzonitrile 9. 4-((((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methoxy)methyl)benzonitrile **6** (25 mg, 45 μmol) was dissolved in a 5:2 mixture of TFA/ H_2O (1.4 mL) and stirred at room temperature for 30 minutes. The solvent was then removed under reduced pressure to give the crude product, which was purified by reverse-phase C18 chromatography with the Biotage SP1 purification system (water/MeCN + 0.1% formic acid, 70:30 to 0:100) to give the title compound **9** as a colorless oil (11 mg, 47%); ^1H NMR (600 MHz, DMSO- d_6) δH 7.89 (s, 1H), 7.72 (d, J = 7.8 Hz, 2H), 7.38 (d, J = 7.9 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H), 7.11 (app. t, J = 6.1 Hz, 1H), 6.47 (br. s, 2H), 5.86 (d, J = 5.6 Hz, 1H), 5.38 (d, J = 5.8, 1H), 5.21 (d, J = 5.2 Hz, 1H), 4.93 (app. q, J = 5.6

Hz, 1H), 4.55 – 4.49 (m, 2H), 4.49 – 4.41 (m, 2H), 4.31 (app. q, J = 5.0 Hz, 1H), 4.03 (app. q, J = 4.0 Hz, 1H), 3.76 (dd, J = 10.9, 3.1 Hz, 1H), 3.64 (dd, J = 10.8, 4.5 Hz, 1H); ^{13}C NMR (151 MHz, DMSO- d_6) δC 152.48, 151.30, 149.88, 148.91, 143.79, 138.75, 132.13, 131.22, 128.84, 128.07, 127.70, 118.75, 116.92, 110.11, 86.95, 82.78, 71.43, 70.46, 70.39, 70.28, 44.60; HRMS (ESI) $\text{C}_{25}\text{H}_{25}\text{N}_7\text{O}_4^{35}\text{Cl}$ ($\text{M}+\text{H}^+$) requires 522.1651, found 522.1570; $t\text{R}$ (LCMS) = 1.32 min; IR (FTIR-ATR)/ cm^{-1} = 3432, 3325, 3232, 2925, 2230, 1651, 1612, 1595, 1573, 1531, 1490, 1443, 1333, 1299.

((3a*R*,4*R*,6*R*,6a*R*)-6-(6-amino-8-bromo-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol 11. 2',3'-*O*-isopropylideneadenosine **10** (1.17 g, 3.81 mmol) was dissolved in 1,4-dioxane (16 mL) and stirred to dissolution. $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$ (2.61 g, 11.4 mmol) was dissolved in water (16 mL) then added to bromine (1.52 g, 9.52 mmol). The bromine solution was added dropwise to the stirred adenosine solution at room temperature. After 30 minutes the reaction was quenched with sat. aq. $\text{Na}_2\text{S}_2\text{O}_3$ solution (30 mL) and stirred for a further 2 minutes. The resulting mixture was extracted with EtOAc (3 x 100 mL), then the combined organic layers washed with sat. NaCl and dried over Na_2SO_4 . The solvent was removed under reduced pressure and the crude product was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 80:20) to give the title compound **11** as an orange solid (1.1 g, 74%); ^1H NMR (500 MHz, DMSO- d_6) δH

8.15 (s, 1H), 7.56 (s, 2H), 6.02 (d, J = 2.7 Hz, 1H), 5.66 (dd, J = 6.2, 2.7 Hz, 1H), 5.12 (dd, J = 6.3, 5.5 Hz, 1H), 5.03 (dd, J = 6.2, 3.0 Hz, 1H), 4.16 (td, J = 5.8, 3.0 Hz, 1H), 3.52 (dt, J = 11.5, 5.5 Hz, 1H), 3.43 (dt, J = 11.5, 6.3 Hz, 1H), 1.55 (s, 3H), 1.33 (s, 3H); ^{13}C NMR (126 MHz, DMSO- d_6) δ C 154.1, 151.6, 149.6, 126.9, 119.3, 113.3, 91.0, 87.3, 82.0, 81.6, 61.4, 27.1, 25.3; HRMS (ESI) $\text{C}_{13}\text{H}_{17}\text{N}_5\text{O}_4^{79}\text{Br}$ ($\text{M}+\text{H}^+$) requires 386.0458, found 386.0456; tR (LCMS) = 1.22 min; IR (FTIR-ATR)/ cm^{-1} = 3321, 3172, 2953, 2851, 1657, 1596, 1575, 1497, 1461.

((3a*R*,4*R*,6*R*,6a*R*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-

dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol 12. ((3a*R*,4*R*,6*R*,6a*R*)-6-(6-amino-8-

bromo-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol **11** (1.71 g,

4.44 mmol) and 4-chlorobenzylamine (5.03 g, 35.5 mmol) were dissolved in EtOH (15 mL)

and the reaction was heated in the microwave for 1 hour at 160 °C. The solvent was removed

under reduced pressure and the resulting residue taken up in EtOAc (50 mL), washed with

1% AcOH solution (3 x 50 mL) and sat. aq. NaHCO_3 solution (3 x 50 mL), dried over MgSO_4 .

The solvent was removed under reduced pressure and the crude product was purified by silica

gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 70:30) to

give the title compound **12** as an orange solid (1.93 g, 97%); ^1H NMR (500 MHz, DMSO- d_6)

δ H 7.93 (s, 1H), 7.61 (t, J = 6.0 Hz, 1H), 7.40 (d, J = 8.8 Hz, 2H), 7.38 (d, J = 8.8 Hz, 2H), 6.57

(s, 2H), 6.09 (d, J = 3.5 Hz, 1H), 5.47 (dd, J = 6.2, 3.5 Hz, 1H), 5.42 (app. t, J = 5.2 Hz, 1H), 4.97 (dd, J = 6.3, 2.8 Hz, 1H), 4.58 (dd, J = 15.6, 5.8 Hz, 1H), 4.53 (dd, J = 15.6, 6.0 Hz, 1H), 4.17 (app. td, J = 4.4, 2.8 Hz, 1H), 3.59 – 3.49 (m, 2H), 1.55 (s, 3H), 1.32 (s, 3H); ^{13}C NMR (126 MHz, DMSO- d_6) δ 153.04, 151.44, 149.69, 149.39, 139.23, 131.75, 129.63, 128.62, 117.45, 113.62, 88.37, 85.86, 81.85, 81.63, 61.82, 45.20, 27.61, 25.73; HRMS (ESI) $\text{C}_{20}\text{H}_{24}\text{N}_6\text{O}_4^{35}\text{Cl}$ ($\text{M}+\text{H}^+$) requires 447.1542, found 447.1525; t_R (LCMS) = 1.36 min; IR (FTIR-ATR)/ cm^{-1} = 3190, 2934, 1645, 1607, 1573, 1491, 1457, 1371, 1326, 1213.

((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate 13.

((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-

dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol **12** (0.37 g, 0.82 mmol) was dissolved in DMF (8.2 mL) and cooled to 0 °C. Triethylamine (0.12 g, 1.24 mmol), then 4-(fluorosulfonyl)benzoyl chloride (0.22 g, 0.99 mmol) were added and the reaction stirred at 0 °C for 4 hours. The solvent was removed under reduced pressure and the subsequent oil was taken up in EtOAc (30 mL), washed with sat. NaCl (3 x 30 mL) and dried over MgSO_4 . The solvent was removed under reduced pressured to give the crude product, which was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 80:20) to give the title compound **13** as an orange solid (0.29 g, 56%); ^1H NMR (600 MHz,

CDCl₃) δH 8.11 (s, 1H), 8.05 (d, *J* = 8.5 Hz, 2H), 7.99 (d, *J* = 8.6 Hz, 2H), 7.30 (app. s, 4H), 6.13 (dd, *J* = 6.1, 1.6 Hz, 1H), 5.90 (d, *J* = 1.6 Hz, 1H), 5.18 (dd, *J* = 6.1, 3.1 Hz, 1H), 5.14 (s, 2H), 5.02 (app. t, *J* = 5.7 Hz, 1H), 4.62 (dd, *J* = 14.5, 6.1 Hz, 1H), 4.56 – 4.49 (m, 3H), 4.39 (dd, *J* = 11.8, 5.8 Hz, 1H), 1.60 (s, 3H), 1.44 (s, 3H); ¹³C NMR (151 MHz, CDCl₃) δC 164.02, 152.36, 151.76, 150.14, 149.84, 137.04 (d, *J* = 25.6 Hz), 136.69, 135.61, 133.73, 130.70, 129.24, 129.05, 128.54, 117.85, 114.44, 89.61, 85.43, 82.52, 81.71, 64.87, 46.59, 27.25, 25.55; ¹⁹F NMR (471 MHz, CDCl₃) δF 65.68; HRMS (ESI) C₂₇H₂₇N₆O₇SF³⁵Cl (M+H⁺) requires 633.1329, found 633.1360; tR (LCMS) = 1.57 min; IR (FTIR-ATR)/cm⁻¹ = 3192, 1675, 1600, 1492, 1410, 1270, 1211.

((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methyl 4-(fluorosulfonyl)benzoate 14. ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate **13** (77 mg, 0.12 mmol) was dissolved in a 5:2 mixture of TFA/H₂O (1.4 mL) and stirred at room temperature for 30 minutes. The solvent was then removed under reduced pressure to give the crude product, which was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 80:20) to give the title compound **14** as an off white solid (24 mg, 32%); ¹H NMR (500 MHz, DMSO-*d*₆) δH 8.20 (d, *J* = 8.6 Hz, 2H), 8.12 (d, *J* = 8.4 Hz, 2H), 7.81 (s, 1H), 7.49 (app. t, *J* = 6.0 Hz, 1H),

7.38 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 6.46 (s, 2H), 5.81 (d, J = 4.0 Hz, 1H), 5.46 (d, J = 5.2 Hz, 1H), 5.33 (d, J = 5.9 Hz, 1H), 5.19 (app. q, J = 5.2 Hz, 1H), 4.70 – 4.63 (m, 2H), 4.53 (app. d, J = 5.9 Hz, 2H), 4.46 (dd, J = 12.0, 5.0 Hz, 1H), 4.16 (app. td, J = 5.3, 3.2 Hz, 1H); ^{13}C NMR (126 MHz, DMSO-d_6) δC 163.82, 152.50, 151.67, 149.52, 148.78, 138.87, 136.18, 135.21 (d, J = 24.0 Hz), 131.22, 130.75, 129.21, 128.77, 128.04, 117.29, 87.67, 80.52, 70.75, 69.65, 64.78, 44.74; ^{19}F NMR (471 MHz, DMSO-d_6) δF 66.03; HRMS (ESI) $\text{C}_{24}\text{H}_{23}\text{N}_6\text{O}_7\text{SF}^{35}\text{Cl}$ ($\text{M}+\text{H}^+$) requires 593.1016, found 593.1008; $t\text{R}$ (LCMS) = 1.41 min; IR (FTIR-ATR)/ cm^{-1} = 3346, 1726, 1637, 1608, 1573, 1409, 1270, 1210.

((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((4-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methyl 4-cyanobenzoate 15. ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-

((4-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-

yl)methanol **12** (0.11 g, 0.24 mmol) was dissolved in DMF (2.4 mL) and cooled to 0 °C.

Triethylamine (36 mg, 0.36 mmol), then 4-cyanobenzoyl chloride (47 mg, 0.28 mmol) were

added and the reaction stirred at 0 °C for 3 hours. The solvent was removed under reduced

pressure to give the crude product, which was purified by silica gel chromatography with the

Biotage SP1 purification system (EtOAc/EtOH 95:5 to 70:30) to give ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-

amino-8-((4-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-

4-yl)methyl 4-cyanobenzoate as a yellow oil (45 mg, 33%); ^1H NMR (500 MHz, CDCl_3) δH

8.11 (s, 1H), 7.93 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 7.29 (s, 4H), 6.09 (dd, J = 6.2, 1.7 Hz, 1H), 5.91 (d, J = 1.7 Hz, 1H), 5.25 (s, 2H), 5.15 (dd, J = 6.2, 3.2 Hz, 1H), 5.07 (app. t, J = 5.7, 1H), 4.61 (dd, J = 14.6, 6.1 Hz, 1H), 4.56 – 4.51 (m, 2H), 4.46 (dd, J = 11.9, 4.7 Hz, 1H), 4.36 (dd, J = 11.9, 6.0 Hz, 1H), 1.60 (s, 3H), 1.43 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 164.51, 152.35, 151.79, 150.01, 149.86, 136.69, 133.70, 133.09, 132.28, 130.15, 129.20, 129.03, 117.97, 117.82, 116.84, 114.50, 89.62, 85.22, 82.50, 81.65, 64.61, 46.56, 27.24, 25.55; HRMS (ESI) $\text{C}_{28}\text{H}_{27}\text{N}_7\text{O}_5^{35}\text{Cl}$ ($\text{M}+\text{H}^+$) requires 576.1757, found 576.1746; t_R (LCMS) = 1.51 min. ((*3aR,4R,6R,6aR*)-6-(6-amino-8-((4-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-cyanobenzoate was dissolved in a 5:2 mixture of TFA/ H_2O (1.4 mL) and stirred at room temperature for 45 minutes. The solvent was then removed under reduced pressure to give the crude product, which was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 95:5 to 65:35) to give the title compound **15** as a yellow oil (16 mg, 48%); ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.93 (d, J = 8.9 Hz, 2H), 7.91 (d, J = 8.9 Hz, 2H), 7.83 (s, 1H), 7.48 (app. t, J = 6.0 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 6.49 (br. s, 2H), 5.79 (d, J = 3.9 Hz, 1H), 5.45 (d, J = 5.2 Hz, 1H), 5.31 (d, J = 5.9 Hz, 1H), 5.22 (app. td, J = 5.3, 4.0 Hz, 1H), 4.65 (app. q, J = 5.8 Hz, 1H), 4.61 (dd, J = 12.4, 3.5 Hz, 1H), 4.53 (app. d, J = 5.9 Hz, 2H), 4.42 (dd, J = 12.0, 4.7 Hz, 1H), 4.14 (ddd, J = 6.2, 4.6, 3.2 Hz, 1H); ^{13}C NMR (126 MHz, $\text{DMSO}-d_6$) δ C

164.28, 152.50, 151.71, 149.51, 148.78, 138.87, 133.30, 132.64, 131.21, 129.74, 129.19, 128.03, 118.04, 117.29, 115.45, 87.65, 80.46, 70.72, 69.56, 64.32, 44.73; HRMS (ESI) $C_{25}H_{23}N_7O_5^{35}Cl$ ($M+H^+$) requires 536.1444, found 536.1418; tR (LCMS) = 1.32 min; IR (FTIR-ATR)/ cm^{-1} = 3364, 6101, 2233, 1720, 1611, 1574, 1480, 1435, 1270.

((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-9*H*-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 4-(fluorosulfonyl)benzoate **16**. 2',3'-*O*-isopropylideneadenosine **10** (0.15 g, 0.49 mmol) was dissolved in DMF (2.5 mL). 4-(Fluorosulfonyl)benzoic acid (0.12 g, 0.59 mmol), triethylamine (99 mg, 0.98 mmol) and HBTU (0.22 g, 0.59 mmol) were added and the reaction stirred at room temperature for 2 hours. The solvent was then removed under reduced pressure to give an orange oil that was taken up in EtOAc (20 mL), washed with sat. aq. $NaHCO_3$ (2 x 20 mL), sat. NaCl (2 x 20 mL) and dried over $MgSO_4$. The solvent was removed under reduced pressure and the crude product was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 70:30) to give ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate as an orange foam (0.16 g, 66%); 1H NMR (600 MHz, $CDCl_3$) δ H 8.30 (s, 1H), 8.17 (d, J = 8.3 Hz, 2H), 8.04 (d, J = 8.6 Hz, 2H), 7.86 (s, 1H), 6.10 (d, J = 1.9 Hz, 1H), 5.70 (br. s, 2H), 5.60 (dd, J = 6.3, 1.9 Hz, 1H), 5.23 (dd, J = 6.3, 3.6 Hz, 1H), 4.69 (dd, J = 11.5, 4.1 Hz, 1H), 4.60 (app. dt, J = 6.3, 3.9 Hz, 1H), 4.55 (dd, J = 11.5, 6.3 Hz, 1H),

1.64 (s, 3H), 1.42 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δC 164.11, 155.63, 153.31, 149.28, 140.21, 137.03 (d, $J = 25.4$ Hz), 135.98, 130.89, 128.59, 120.57, 114.93, 91.24, 85.19, 84.17, 81.80, 65.42, 27.34, 25.57; ^{19}F NMR (471 MHz, CDCl_3) δF 65.78; HRMS (ESI) $\text{C}_{20}\text{H}_{21}\text{N}_5\text{O}_7\text{FS}$ ($\text{M}+\text{H}^+$) requires 494.1140, found 494.1152; $t\text{R}$ (LCMS) = 1.40 min. ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate (60 mg, 0.12 mmol) was dissolved in a 5:2 mixture of TFA/ H_2O (1.4 mL) and stirred at room temperature for 1 hour. The solvent was then removed under reduced pressure to give the crude product, which was purified by reverse-phase C18 chromatography with the Biotage SP1 purification system (water/MeCN + 1% formic acid, 90:10 to 40:60) to give the title compound **16** as an orange oil (41 mg, 74%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δH 8.31 (s, 1H), 8.27 (d, $J = 8.7$ Hz, 2H), 8.25 (d, $J = 8.7$ Hz, 2H), 8.06 (s, 1H), 7.28 (br. s, 2H), 5.93 (d, $J = 4.7$ Hz, 1H), 5.59 (d, $J = 5.7$ Hz, 1H), 5.43 (d, $J = 5.5$ Hz, 1H), 4.77 (app. q, $J = 5.2$ Hz, 1H), 4.68 (dd, $J = 12.0, 3.6$ Hz, 1H), 4.52 (dd, $J = 12.0, 5.9$ Hz, 1H), 4.47 (app. q, $J = 5.3$ Hz, 1H), 4.24 (app. td, $J = 5.5, 3.6$ Hz, 1H); ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δC 163.88, 156.07, 152.58, 149.20, 140.12, 136.26, 135.28 (d, $J = 24.0$), 130.92, 128.89, 119.25, 88.18, 81.18, 72.65, 70.10, 65.27; ^{19}F NMR (471 MHz, $\text{DMSO}-d_6$) δF 65.99; HRMS (ESI) $\text{C}_{17}\text{H}_{17}\text{N}_5\text{O}_7\text{FS}$ ($\text{M}+\text{H}^+$) requires 454.0827, found 454.0804; $t\text{R}$ (LCMS) = 1.15 min; IR (FTIR-ATR)/ cm^{-1} = 3378, 3095, 1738, 1682, 1608, 1576, 1483, 1407, 1378.

1
2
3
4 ((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-(methylamino)-9*H*-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
5
6
7 yl)methyl 4-(fluorosulfonyl)benzoate 17. ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-bromo-9*H*-purin-9-
8
9
10 yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol 11 (0.40 g, 1.04 mmol) was
11
12
13 dissolved in 33% methylamine in ethanol (5.2 mL) and heated in the microwave for 1 hour at
14
15
16 160 °C. The solvent was removed under reduced pressure and the crude product was purified
17
18
19 by reverse-phase C18 chromatography with the Biotage SP1 purification system (water/MeCN
20
21
22 + 1% formic acid, 90:10 to 40:60) to give ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-amino-8-(methylamino)-9*H*-
23
24
25 purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol as an orange oil (0.27 g,
26
27
28 77%); ¹H NMR (500 MHz, CDCl₃) δH 8.06 (s, 1H), 6.41 (s, 2H), 6.00 (d, *J* = 4.2 Hz, 1H), 5.76
29
30
31 (app. s, 1H), 5.14 (dd, *J* = 6.5, 4.2 Hz, 1H), 5.03 (dd, *J* = 6.4, 2.7 Hz, 1H), 4.36 (app. q, *J* = 2.2
32
33
34 Hz, 1H), 3.98 (dd, *J* = 12.1, 2.2 Hz, 1H), 3.85 (dd, *J* = 12.1, 2.1 Hz, 1H), 2.95 (app. s, 3H),
35
36
37 1.62 (s, 3H), 1.36 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δC 152.52, 151.40, 149.30, 147.87,
38
39
40 117.23, 114.85, 90.03, 85.38, 82.67, 80.74, 62.16, 29.72, 27.54, 25.38; HRMS (ESI)
41
42
43 C₁₄H₂₁N₆O₄ (M+H⁺) requires 337.1619, found 337.1608; tR (LCMS) = 0.93 min; IR (FTIR-
44
45
46 ATR)/cm⁻¹ = 3184, 1612, 1581, 1434, 1472, 1376, 1337, 1285, 1211. ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-
47
48
49 amino-8-(methylamino)-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-
50
51
52 yl)methanol (65 mg, 0.19 mmol) was dissolved in DMF (1.9 mL). 4-(Fluorosulfonyl)benzoic
53
54
55 acid (47 mg, 0.23 mmol), triethylamine (39 mg, 0.39 mmol) and HBTU (88 mg, 0.23 mmol)
56
57
58
59
60

were added and the reaction stirred at room temperature for 5 hours. The solvent was then removed under reduced pressure to give an orange oil that was taken up in EtOAc (20 mL), washed with sat. aq. NaHCO₃ (2 x 20 mL), sat. NaCl (2 x 20 mL) and dried over MgSO₄. The solvent was removed under reduced pressure and the crude product was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 60:40) to give ((*3aR,4R,6R,6aR*)-6-(6-amino-8-(methylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate as an orange oil (70% pure by LCMS) that was used without further purification; t_R (LCMS) = 1.32 min.

((*3aR,4R,6R,6aR*)-6-(6-amino-8-(methylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate) was dissolved in a 5:2 mixture of TFA/H₂O (1.4 mL) and stirred at room temperature for 1 hour. The solvent was then removed under reduced pressure to give the crude product, which was purified by reverse-phase C18 chromatography with the Biotage SP1 purification system (water/MeCN + 1% formic acid, 90:10 to 40:60) to give the title compound **17** as an orange oil (11 mg, 40%); ¹H NMR (600 MHz, MeOD) δH 8.07 (app. s, 4H), 7.85 (s, 1H), 5.70 (d, *J* = 3.4 Hz, 1H), 5.38 (dd, *J* = 5.4, 3.4 Hz, 1H), 4.86 – 4.83 (obs. m, 1H), 4.80 (dd, *J* = 12.2, 3.1 Hz, 1H), 4.53 (dd, *J* = 12.2, 4.0 Hz, 1H), 4.29 (app. dt, *J* = 6.7, 3.5 Hz, 1H), 2.66 (s, 3H); ¹³C NMR (151 MHz, MeOD) δC 165.46, 154.87, 153.26, 150.78, 150.18, 137.49, 131.71, 129.62, 90.04,

82.91, 72.77, 71.45, 65.03, 40.43, 29.60; ¹⁹F NMR (471 MHz, MeOD) δF 63.73; tR (LCMS) = 1.07 min.

((2*R*,3*S*,4*R*,5*R*)-5-(6-amino-8-((quinolin-6-ylmethyl)amino)-9*H*-purin-9-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methyl 4-(fluorosulfonyl)benzoate 18. ((3*aR*,4*R*,6*R*,6*aR*)-6-(6-

amino-8-bromo-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol 11

(0.62 g, 1.61 mmol) was dissolved in EtOH (8.0 mL) and added to quinolin-6-ylmethanamine

(1.11 g, 7.2 mmol) and the reaction was heated in the microwave for 2 hours at 160 °C. The

solvent was removed under reduced pressure and the resulting residue taken up in EtOAc (50

mL) and 1% aq. AcOH (50 mL). The product was extracted with EtOAc (3 x 40 mL), washed

with 1% aq. AcOH (3 x 40 mL), sat. aq. NaHCO₃ (3 x 40 mL) and sat. NaCl (40 mL) and dried

over Na₂SO₄. The solvent was removed under reduced pressure and the crude product was

purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH

95:5 to 50:50), followed by reverse-phase C18 chromatography with the Biotage SP1

purification system (water/MeCN + 1% formic acid, 80:20 to 0:100) to give ((3*aR*,4*R*,6*R*,6*aR*)-

6-(6-amino-8-((quinolin-6-ylmethyl)amino)-9*H*-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-

d][1,3]dioxol-4-yl)methanol as a yellow oil (60 mg, 8%); ¹H NMR (600 MHz, MeOD) δH 8.80

(dd, *J* = 4.5, 1.7 Hz, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 8.12 (app. s, 1H), 8.01 (s, 1H), 7.91 (app.

s, 1H), 7.83 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.51 (dd, *J* = 8.3, 4.3 Hz, 1H), 6.23 (d, *J* = 4.3 Hz, 1H),

5.34 (dd, $J = 6.4, 4.3$ Hz, 1H), 5.03 (dd, $J = 6.3, 2.6$ Hz, 1H), 4.86 – 4.79 (obs. m, 2H), 4.34 (app. q, $J = 2.8$ Hz, 1H), 3.82 (dd, $J = 11.7, 3.0$ Hz, 1H), 3.76 (dd, $J = 11.7, 2.7$ Hz, 1H), 1.63 (s, 3H), 1.37 (s, 3H); ^{13}C NMR (151 MHz, MeOD) δC 153.20, 150.93, 150.69, 149.99, 148.07, 139.18, 138.36, 130.76, 129.30, 126.62, 122.75, 117.92, 115.63, 90.58, 86.56, 83.26, 82.43, 62.80, 46.85, 44.55, 40.42, 27.62, 25.59; HRMS (ESI) $\text{C}_{23}\text{H}_{26}\text{N}_7\text{O}_4$ ($\text{M}+\text{H}^+$) requires 464.2041, found 464.2023; $t\text{R}$ (LCMS) = 0.97 min. ((*3aR,4R,6R,6aR*)-6-(6-amino-8-((quinolin-6-ylmethyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methanol (0.14 g, 0.30 mmol) was dissolved in DMF (2.9 mL). 4-(Fluorosulfonyl)benzoic acid (72 mg, 0.35 mmol), triethylamine (60 mg, 0.59 mmol) and HBTU (0.13 g, 0.35 mmol) were added and the reaction stirred at room temperature for 2 hours. The solvent was then removed under reduced pressure to give an orange oil that was taken up in EtOAc (20 mL), washed with sat. aq. NaHCO_3 (2 x 20 mL), sat. NaCl (2 x 20 mL) and dried over MgSO_4 . The solvent was removed under reduced pressure and the crude product was purified by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 100:0 to 60:40) to give ((*3aR,4R,6R,6aR*)-6-(6-amino-8-((quinolin-6-ylmethyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate as an orange oil (77 mg, 40%); ^1H NMR (600 MHz, CDCl_3) δH 8.90 (dd, $J = 4.2, 1.7$ Hz, 1H), 8.11 – 8.08 (m, 2H), 8.06 (d, $J = 8.6$ Hz, 1H), 8.00 (d, $J = 8.3$ Hz, 2H), 7.93 (d, $J = 8.6$ Hz, 2H), 7.74 (s,

1H), 7.71 (dd, J = 8.7, 2.0 Hz, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 6.13 (dd, J = 6.1, 1.6 Hz, 1H), 5.97 (d, J = 1.6 Hz, 1H), 5.28 (app. t, J = 5.7 Hz, 1H), 5.21 (br. s, 2H), 5.18 (dd, J = 6.2, 2.8 Hz, 1H), 4.85 (dd, J = 14.7, 6.1 Hz, 1H), 4.75 (dd, J = 14.7, 5.2 Hz, 1H), 4.55 – 4.50 (m, 2H), 4.43 – 4.37 (m, 1H), 1.58 (s, 3H), 1.43 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δC 164.00, 152.38, 151.86, 150.71, 150.10, 149.86, 147.92, 136.95 (d, J = 25.6 Hz), 136.56, 135.99, 135.55, 130.64, 130.23, 129.44, 128.46, 128.25, 126.21, 121.67, 117.89, 114.46, 89.60, 85.36, 82.53, 81.68, 64.87, 47.08, 27.23, 25.55; ^{19}F NMR (471 MHz, CDCl_3) δF 65.69; HRMS (ESI) $\text{C}_{30}\text{H}_{29}\text{N}_7\text{O}_7\text{FS}$ ($\text{M}+\text{H}^+$) requires 650.1828, found 650.1810; $t\text{R}$ (LCMS_extended) = 2.55 min; IR (FTIR-ATR)/ cm^{-1} = 3328, 1725, 1635, 1606, 1572, 1503, 1410, 1374, 1329, 1268, 1210. ((*3aR,4R,6R,6aR*)-6-(6-amino-8-((quinolin-6-ylmethyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 4-(fluorosulfonyl)benzoate (68 mg, 0.10 mmol) was dissolved in a 5:2 mixture of TFA/ H_2O (1.4 mL) and stirred at room temperature for 30 minutes. The solvent was then removed under reduced pressure to give the crude product, which was purified by reverse-phase C18 chromatography with the Biotage SP1 purification system (water/MeCN + 1% formic acid, 90:10 to 60:40), followed by silica gel chromatography with the Biotage SP1 purification system (EtOAc/EtOH 95:5 to 40:60) to give the title compound **18** as an amorphous yellow solid (7 mg, 11%); ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δH 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.28 (dd, J = 8.5, 0.9 Hz, 1H), 8.18 (d, J = 8.6 Hz, 2H),

8.10 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 0.7 Hz, 1H), 7.82 (s, 1H), 7.78 (dd, J = 8.7, 2.0 Hz, 1H), 7.59 (app. t, J = 6.0 Hz, 1H), 7.48 (dd, J = 8.3, 4.2 Hz, 1H), 6.46 (br. s, 2H), 5.86 (d, J = 4.0 Hz, 1H), 5.47 (d, J = 5.2 Hz, 1H), 5.33 (d, J = 5.8 Hz, 1H), 5.22 (app. q, J = 5.0 Hz, 1H), 4.76 (app. d, J = 5.8 Hz, 2H), 4.70 (dd, J = 12.0, 3.2 Hz, 1H), 4.66 (app. q, J = 5.8 Hz, 1H), 4.47 (dd, J = 12.0, 5.0 Hz, 1H), 4.17 (app. td, J = 5.3, 3.2 Hz, 1H); ^{13}C NMR (151 MHz, DMSO- d_6) δC 163.81, 152.52, 151.78, 150.07, 149.54, 148.78, 147.02, 138.09, 136.13, 135.66, 135.17 (d, J = 24.3 Hz), 130.70, 129.55, 128.79, 128.72, 127.57, 125.60, 121.49, 117.32, 87.72, 80.55, 70.78, 69.65, 64.78, 45.42; ^{19}F NMR (471 MHz, DMSO- d_6) δF 66.03; HRMS (ESI) $\text{C}_{27}\text{H}_{25}\text{N}_7\text{O}_7\text{FS}$ ($\text{M}+\text{H}^+$) requires 610.1515, found 610.1499; $t\text{R}$ (LCMS_extended) = 2.04 min; IR (FTIR-ATR)/ cm^{-1} = 3324, 1724, 1635, 1608, 1573, 1505, 1409, 1330, 1270, 1210.

ASSOCIATED CONTENT

Supporting Information.

The Supporting Information is available free of charge on the ACS Publications website at DOI:

Computational chemistry methods, worked example of the covalent FP-assay, covalent FP and intact-protein MS figures, NMR spectra of final compounds (PDF)

Covalent FP worked example (xlsx)

SMILES molecular formula strings (CSV)

AUTHOR INFORMATION

Corresponding Author

*Phone, (+44) 208 722 4168; E-mail, matthew.cheeseman@icr.ac.uk

ORCID

Jonathan Pettinger 0000-0002-8219-8369

Keith Jones: 0000-0002-9440-4094

Matthew D. Cheeseman: 0000-0003-1121-6985

Author Contributions

J.P. synthesized the compounds and carried out the biochemical analysis. M.C.

carried out the ROCS conformational analysis. J.P., K.J. and M.D.C. designed the

compounds and interpreted the data. J.P. and M.D.C. designed the covalent FP

assay. J.P. and M.D.C. wrote the manuscript. All authors have given approval to the

final version of the manuscript.

Funding Sources

This work was funded by an ICR Chairman's Studentship Award (JP) and Cancer Research UK grants (C309/A8274, C309/A11566).

Notes

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

The authors would like to thank Katia Grira, Meirion Richards, Maggie Liu, and Amin Mirza of the Structural Chemistry team for their expertise and assistance.

ABBREVIATIONS

MOA, mechanism of action; TCI, targeted covalent inhibitor; E, enzyme/protein; EI, reversible enzyme/protein-inhibitor complex; E-I, irreversible enzyme/protein-inhibitor covalent complex; I, inhibitor/ligand; EI*, pre-covalent complex; K_i , equilibrium constant; k_{inact} , first-order rate constant for covalent inhibition; $t_{1/2}^{inf}$, theoretical half-life at infinite concentration; K_i , concentration at $k_{inact}/2$; k_{obs} , observed first-order rate constant; k_{off} , dissociation rate constant; k_{on} , association rate constant; %CO, percentage covalent occupancy; percentage total occupancy; HSP72, Heat shock 70 kDa protein 1; KRAS, GTPase KRas; HSF1, Heat shock factor protein 1; NBD,

nucleotide-binding domain; K_m , Michaelis-Menten constant; SAR, structure activity relationship; FP, fluorescence polarization; SF, *p*-sulfonyl fluoride; ROCS, rapid overlay of chemical structures; CSD, Cambridge Structural Database; PI3K δ , Phosphoinositide 3-kinase delta; S_NAr , substitution nucleophilic aromatic; MMP, molecular matched pair; MS, mass spectrometry; SEM, standard error of the mean; NA, not applicable; ND, not determined; App., apparent; S_AN , substitution associative nucleophilic; F_b , fraction bound; A, anisotropy; mP, millipolarization; min, minutes; h, hours; WT, wild-type; FO, fractional reversible occupancy; sat. saturated; cyc, cyclohexane; EtOAc, ethyl acetate; AcOH, acetic acid; DMF, dimethylformamide; aq. aqueous; DIPEA, diisopropylethylamine; EtOH, ethanol; MeOH, methanol; MeCN acetonitrile; HATU, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate; HBTU, *N,N,N',N'*-Tetramethyl-*O*-(1H-benzotriazol-1-yl)uronium hexafluorophosphate,.

REFERENCES

(1) Baillie, T. A. Targeted covalent inhibitors for drug design. *Angew. Chem., Int. Ed. Engl.* **2016**, *55*, 13408-13421.

(2) Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. *Future Med. Chem.* **2010**, *2*, 949-964.

(3) Bauer, R. A. Covalent inhibitors in drug discovery: From accidental discoveries to avoided liabilities and designed therapies. *Drug Discovery Today* **2015**, *20*, 1061-1073.

(4) Engel, J.; Richters, A.; Getlik, M.; Tomassi, S.; Keul, M.; Termathe, M.; Lategahn, J.; Becker, C.; Mayer-Wrangowski, S.; Grütter, C.; Uhlenbrock, N.; Krüll, J.; Schaumann, N.; Eppmann, S.; Kibies, P.; Hoffgaard, F.; Heil, J.; Menninger, S.; Ortiz-Cuaran, S.; Heuckmann, J. M.; Tinnefeld, V.; Zahedi, R. P.; Sos, M. L.; Schultz-Fademrecht, C.; Thomas, R. K.; Kast, S. M.; Rauh, D. Targeting drug resistance in egfr with covalent inhibitors: A structure-based design approach. *J. Med. Chem.* **2015**, *58*, 6844-6863.

(5) Marino, S. M.; Gladyshev, V. N. Cysteine function governs its conservation and degeneration and restricts its utilization on protein surfaces. *J. Mol. Biol.* **2010**, *404*, 902-916.

(6) Jakob, C. G.; Upadhyay, A. K.; Donner, P. L.; Nicholl, E.; Addo, S. N.; Qiu, W.; Ling, C.; Gopalakrishnan, S. M.; Torrent, M.; Cepa, S. P.; Shanley, J.; Shoemaker, A. R.; Sun, C. C.; Vasudevan, A.; Woller, K. R.; Shotwell, J. B.; Shaw, B.; Bian, Z.; Hutti, J. E. Novel modes of inhibition of wild-type isocitrate dehydrogenase 1 (IDH1): Direct covalent modification of his315. *J. Med. Chem.* **2018**, *61*, 6647-6657.

(7) Kharenko, O. A.; Patel, R. G.; Brown, S. D.; Calosing, C.; White, A.; Lakshminarasimhan, D.; Suto, R. K.; Duffy, B. C.; Kitchen, D. B.; McLure, K. G.; Hansen, H. C.; van der Horst, E. H.; Young, P. R. Design and characterization of novel covalent bromodomain and extra-terminal domain (BET) inhibitors targeting a methionine. *J. Med. Chem.* **2018**, *61*, 8202-8211.

(8) Mukherjee, H.; Grimster, N. P. Beyond cysteine: Recent developments in the area of targeted covalent inhibition. *Curr. Opin. Chem. Biol.* **2018**, *44*, 30-38.

(9) Strelow, J. M. A perspective on the kinetics of covalent and irreversible inhibition. *SLAS Discovery* **2016**, *22*, 3-20.

$$(10) t_{1/2}^{inf} = \ln 2 / k_{inact}$$

$$(11) K_i = (k_{off} + k_{inact}) / k_{on}, K_i = k_{off} / k_{on}$$

When $k_{\text{off}} \gg k_{\text{inact}}$ then $k_{\text{off}} + k_{\text{inact}} \approx k_{\text{off}}$ so $K_i \approx K_i$

k_{off} =reversible dissociation first order rate constant of the non-covalent complex EI,

k_{on} =reversible association second order rate constant of the non-covalent complex EI,

k_{inact} =first order rate constant of the covalent complex E-I, K_i =true reversible

equilibrium constant of the non-covalent complex EI, K_i =pseudo reversible equilibrium

constant of the non-covalent complex EI, determined from $k_{\text{obs}} = k_{\text{inact}}/2$,

k_{obs} =concentration dependent pseudo first order rate constant

(12) De Cesco, S.; Kurian, J.; Dufresne, C.; Mittermaier, A. K.; Moitessier, N.

Covalent inhibitors design and discovery. *Eur. J. Med. Chem.* **2017**, *138*, 96-114.

(13) Hansen, R.; Peters, U.; Babbar, A.; Chen, Y.; Feng, J.; Janes, M. R.; Li, L.-S.;

Ren, P.; Liu, Y.; Zarrinkar, P. P. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. *Nat. Struct. Mol. Biol.* **2018**, *25*, 454-462.

(14) Janes, M. R.; Zhang, J.; Li, L.-S.; Hansen, R.; Peters, U.; Guo, X.; Chen, Y.;

Babbar, A.; Firdaus, S. J.; Darjania, L.; Feng, J.; Chen, J. H.; Li, S.; Li, S.; Long, Y. O.;

Thach, C.; Liu, Y.; Zariéh, A.; Ely, T.; Kucharski, J. M.; Kessler, L. V.; Wu, T.; Yu, K.;

Wang, Y.; Yao, Y.; Deng, X.; Zarrinkar, P. P.; Brehmer, D.; Dhanak, D.; Lorenzi, M.

V.; Hu-Lowe, D.; Patricelli, M. P.; Ren, P.; Liu, Y. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. *Cell* **2018**, *172*, 578-589.e17.

(15) Fernández-Fernández, M.; Valpuesta, J. HSP70 chaperone: A master player in protein homeostasis [version 1; peer review: 3 approved]. *F1000Research* **2018**, *7*.

(16) Kumar, S.; Stokes, J.; Singh, U. P.; Scisum Gunn, K.; Acharya, A.; Manne, U.; Mishra, M. Targeting HSP70: A possible therapy for cancer. *Cancer Lett.* **2016**, *374*, 156-166.

(17) Powers, M. V.; Jones, K.; Barillari, C.; Westwood, I.; Montfort, R. L. M. v.; Workman, P. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? *Cell Cycle* **2010**, *9*, 1542-1550.

(18) Williamson, D. S.; Borgognoni, J.; Clay, A.; Daniels, Z.; Dokurno, P.; Drysdale, M. J.; Foloppe, N.; Francis, G. L.; Graham, C. J.; Howes, R.; Macias, A. T.; Murray, J. B.; Parsons, R.; Shaw, T.; Surgenor, A. E.; Terry, L.; Wang, Y.; Wood, M.; Massey, A. J. Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. *J. Med. Chem.* **2009**, *52*, 1510-1513.

(19) Rowlands, M.; McAndrew, C.; Prodromou, C.; Pearl, L.; Kalusa, A.; Jones, K.; Workman, P.; Aherne, W. Detection of the ATPase activity of the molecular chaperones HSP90 and HSP72 using the transcreener ADP assay kit. *J. Biomol. Screening* **2010**, *15*, 279-286.

(20) Pettinger, J.; Le Bihan, Y.-V.; Widya, M.; van Montfort, R. L. M.; Jones, K.; Cheeseman, M. D. An irreversible inhibitor of HSP72 that unexpectedly targets lysine-56. *Angew. Chem., Int. Ed. Engl.* **2017**, *56*, 3536-3540.

(21) Pettinger, J.; Jones, K.; Cheeseman, M. D. Lysine-targeting covalent inhibitors. *Angew. Chem., Int. Ed. Engl.* **2017**, *56*, 15200-15209.

(22) Hacker, S. M.; Backus, K. M.; Lazear, M. R.; Forli, S.; Correia, B. E.; Cravatt, B. F. Global profiling of lysine reactivity and ligandability in the human proteome. *Nat. Chem.* **2017**, *9*, 1181.

(23) Cheeseman, M. D.; Westwood, I. M.; Barbeau, O.; Rowlands, M.; Dobson, S.; Jones, A. M.; Jeganathan, F.; Burke, R.; Kadi, N.; Workman, P.; Collins, I.; van Montfort, R. L. M.; Jones, K. Exploiting protein conformational change to optimize adenosine-derived inhibitors of HSP70. *J. Med. Chem.* **2016**, *59*, 4625-4636.

(24) Jones, A. M.; Westwood, I. M.; Osborne, J. D.; Matthews, T. P.; Cheeseman, M. D.; Rowlands, M. G.; Jeganathan, F.; Burke, R.; Lee, D.; Kadi, N.; Liu, M.; Richards, M.; McAndrew, C.; Yahya, N.; Dobson, S. E.; Jones, K.; Workman, P.; Collins, I.; van Montfort, R. L. M. A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms. *Sci. Rep.* **2016**, *6*, 34701.

(25) Vogt, A. D.; Di Cera, E. Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. *Biochemistry* **2012**, *51*, 5894-5902.

(26) Schlecht, R.; Scholz, S. R.; Dahmen, H.; Wegener, A.; Sirrenberg, C.; Musil, D.; Bomke, J.; Eggenweiler, H.-M.; Mayer, M. P.; Bukau, B. Functional analysis of HSP70 inhibitors. *PLoS One* **2013**, *8*, e78443.

(27) Xinyi, H. Fluorescence polarization competition assay: The range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. *J. Biomol. Screening* **2003**, *8*, 34-38.

(28) $pK_i = -\log K_i$ (M)

(29) Kumar, A.; Zhang, K. Y. J. Advances in the development of shape similarity methods and their application in drug discovery. *Front. Chem. (Lausanne, Switz.)* **2018**, *6*.

(30) The Cambridge Structural Database (CSD); <https://www.ccdc.cam.ac.uk/solutions/csd-system/components/csd/> (accessed July 2019)

(31) Martin, J. S.; MacKenzie, C. J.; Fletcher, D.; Gilbert, I. H. Characterising covalent warhead reactivity. *Bioorg. Med. Chem.* **2019**, *27*, 2066-2074.

(32) Dalton, S. E.; Dittus, L.; Thomas, D. A.; Convery, M. A.; Nunes, J.; Bush, J. T.; Evans, J. P.; Werner, T.; Bantscheff, M.; Murphy, J. A.; Campos, S. Selectively targeting the kinome-conserved lysine of PI3K δ as a general approach to covalent kinase inhibition. *J. Am. Chem. Soc.* **2018**, *140*, 932-939.

(33) Light, S. H.; Minasov, G.; Duban, M.-E.; Anderson, W. F. Adherence to Burgi-Dunitz stereochemical principles requires significant structural rearrangements in Schiff-base formation: Insights from transaldolase complexes. *Acta Crystallogr., Sect. D: Struct. Biol.* **2014**, *70*, 544-552.

(34) Devaraj, N. K.; Perrin, C. L. Approach control. Stereoelectronic origin of geometric constraints on n-to-s and n-to-o acyl shifts in peptides. *Chemical Science* **2018**, *9*, 1789-1794.

(35) Abdul Fattah, T.; Saeed, A.; Albericio, F. Recent advances towards sulfur (vi) fluoride exchange (SUFEX) click chemistry. *J. Fluorine Chem.* **2018**, *213*, 87-112.

(36) Narayanan, A.; Jones, L. H. Sulfonyl fluorides as privileged warheads in chemical biology. *Chem. Sci.* **2015**, *6*, 2650-2659.

(37) Mukherjee, H.; Debreczeni, J.; Breed, J.; Tentarelli, S.; Aquila, B.; Dowling, J. E.; Whitty, A.; Grimster, N. P. A study of the reactivity of S(VI)-F containing warheads with nucleophilic amino-acid side chains under physiological conditions. *Org. Biomol. Chem.* **2017**, *15*, 9685-9695.

(38) Ciuffarin, E.; Senatore, L.; Isola, M. Nucleophilic substitution at four-co-ordinate sulphur. Mobility of the leaving group. *J. Chem. Soc., Perkin Trans. 2 (1972-1999)* **1972**, 468-471.


(39) Schwartz, P. A.; Kuzmic, P.; Solowiej, J.; Bergqvist, S.; Bolanos, B.; Almaden, C.; Nagata, A.; Ryan, K.; Feng, J.; Dalvie, D.; Kath, J. C.; Xu, M.; Wani, R.; Murray, B.

W. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, 173.

(40) Arithmetic mean \pm SEM measured from 3 independent biological repeats.

(41) Evans, L. E.; Jones, K.; Cheeseman, M. D. Targeting secondary protein complexes in drug discovery: Studying the druggability and chemical biology of the HSP70/BAG1 complex. *Chem. Commun.* **2017**, *53*, 5167-5170.

(42) Macias, A. T.; Williamson, D. S.; Allen, N.; Borgognoni, J.; Clay, A.; Daniels, Z.; Dokurno, P.; Drysdale, M. J.; Francis, G. L.; Graham, C. J.; Howes, R.; Matassova, N.; Murray, J. B.; Parsons, R.; Shaw, T.; Surgenor, A. E.; Terry, L.; Wang, Y.; Wood, M.; Massey, A. J. Adenosine-derived inhibitors of 78 kda glucose regulated protein (GRP78) ATPase: Insights into isoform selectivity. *J. Med. Chem.* **2011**, *54*, 4034-4041.



TOC Graphic




Figure 1. Simulated data describing the MOA and kinetic parameters used to quantify the activity of TCIs. (A) TCI two-step binding mechanism. (B) The two components of TCI MOA, both reversible and covalent occupancy contribute to total target occupancy at a given concentration and time. Left = covalent occupancy (%CO) and right total occupancy (%TO), both simulated using $K_i = 1 \mu\text{M}$ and $k_{inact} = 0.069 \text{ min}^{-1}$. FO = fraction reversible occupancy (see supporting information for derivation). (C) Determination of the essential second order rate constant k_{inact}/K_i from the concentration dependent k_{obs} pseudo-first-order rate constant. Left = example where $K_i < [I]$ so k_{inact} and K_i can be deconvoluted. Right = example where $K_i \gg [I]$ so the individual kinetic parameters cannot be distinguished. (D) Nucleoside-derived reversible 1 and covalent inhibitor 2 of HSP72.

1679x1087mm (96 x 96 DPI)




Figure 2. Analysis of Lys56-targeting TCI binding modes. The tertiary conformation of the protein is maintained in the previously described semi-open form in all structures and modeling. The polar interactions of the adenine-type base and ribose are maintained in each binding mode. All diagrams were adapted from analysis using MOE (2014.09) A: Tyr15 up-conformation. The acrylate electrophile of 2 forms a π -stack interaction with Tyr15 and a hydrogen bond with Thr-37. In this reversible complex, the electrophile is too far from Lys56 to form a covalent bond (PDB: 5MKR). B: Tyr15 down-conformation. Following rotation of Tyr15, rotation around the linker of 2 now positions the acrylate electrophile in close proximity to Lys56, suitable for covalent bond formation in this pre-covalent complex. The acrylate moiety was not observed in the electron density due to flexibility so was modelled to estimate distances (PDB: 5MKS). C: Binding mode of the high affinity reversible HSP72 inhibitor 1 in the Tyr15 up-conformation (PDB: 4I08). D: Model of a putative binding mode for a high affinity Lys56-targeting TCI. With Tyr15 in a down-conformation, rotation of the benzylic ether positions a potential para-electrophile at an appropriate distance from Lys56 in a pre-covalent complex. E: Three-step MOA, TCI binds HSP72 to form the reversible complex (EI) before transition to the pre-covalent complex (EI*) that can result in formation of the covalent bond and the irreversible complex (E-I).

1360x1384mm (96 x 96 DPI)






Figure 3. Conformation analysis of the proposed second generation HSP72 TCI. A: Overlay of the acrylate TCI 2 (green) and the high affinity reversible inhibitor 1 (cyan). B: Overlay of the acrylate TCI 2 (green) and the proposed conformation of the second-generation TCI (cyan) in the pre-covalent complex. The generic electrophile is represented as a purple sphere. C: Frequency distribution of torsional angles for 5'-O-adenosine derivatives observed in the CSD, the green line represents the desired torsional angle. D: At the desired torsional angle, the modelled distances to Lys56 from different ring positions.

1223x670mm (96 x 96 DPI)



Scheme 1. Synthesis of the second-generation lysine-56 targeting TCI.

240x154mm (300 x 300 DPI)



Scheme 2. Synthesis of third generation aryl sulfonyl fluoride HSP72 TCIs.

285x151mm (300 x 300 DPI)




Figure 4. The kinetic FP-assay to determine the efficiency of covalent bond formation. 1) Initial titration across a wide range of TCI concentrations and time-points. 2) Extrapolation of the time-dependent change in Fb to t=0. 3) Estimation of Ki from extrapolated t=0 Fb values. 4) A second focused titration on concentrations of TCI<Ki. 5) Gradient of time-dependent change in Fb used to calculate kobs at a given concentration of TCI. 6) The gradient of the rate of change of kobs with [TCI] determines the second order rate constant kinact/KI. 7) By assuming Ki=KI, kinact can be calculated from kinact/KI and converted to t1/2inf. See supporting information for details.

1672x1045mm (96 x 96 DPI)